id|number|supplement_number|device_name|generic_name|date_received|decision_date|description|curated|genetic|companion_diagnostic_device_id|type_id
1|P140020|S020|BRACAnalysis CDx|cancer-related germline gene mutation detection system|2019-12-06 00:00:00|2020-05-19 00:00:00|Approval to expand the intended use of BRACAnalysis CDx to include a companion diagnostic indication for BRCA1/2 mutations in patients with metastatic castration resistant prostate cancer who may benefit from treatment with Lynparza (olaparib).|FALSE|TRUE|1|1
2|P140020|S012|BRACAnalysis CDx|cancer-related germline gene mutation detection system|2017-08-31 00:00:00|2018-01-12 00:00:00|"Approval for the BRACAnalysis CDx. The device is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.Results of the test are used as an aid in identifying breast and ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants| who are or may become eligible for treatment with Lynparza (olaparib). Detection of deleterious or suspected deleterious germline BRCA variants by the BRACAnalysis CDx test in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula (niraparib) maintenance therapy. This assay is for professional use only and is to be performed only at 320 Wakara Way| Salt Lake City| Utah."|FALSE|TRUE|1|1
3|P140020||BRACANALYSIS CDX|cancer-related germline gene mutation detection system|2014-09-24 00:00:00|2014-12-19 00:00:00|"APPROVAL FOR THE BRACANALYSIS CDX. THIS DEVICE IS INDICATED AS FOLLOWS: BRACANALYSIS CDX IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION AND CLASSIFICATION OF VARIANTS IN THE PROTEIN CODING REGIONS AND INTRON/EXON BOUNDARIES OF THE BRCA1 AND BRCA2 GENES USING GENOMIC DNA OBTAINED FROM WHOLE BLOOD SPECIMENS COLLECTED IN EDTA. SINGLE NUCLEOTIDE VARIANTS AND SMALL INSERTIONS AND DELETIONS (INDELS) ARE IDENTIFIED BY POLYMERASE CHAIN REACTION (PCR) AND SANGER SEQUENCING. LARGE DELETIONS AND DUPLICATIONS IN BRCA1 AND BRCA2 ARE DETECTED USING MULTIPLEX PCR. RESULTS OF THE TEST ARE USED AS AN AID IN IDENTIFYING OVARIAN CANCER PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA VARIANTS ELIGIBLE FOR TREATMENT WITH LYNPARZA (OLAPARIB). THIS ASSAY IS FOR PROFESSIONAL USE ONLY AND IS TO BE PERFORMED ONLY AT MYRIAD GENETIC LABORATORIES| A SINGLE LABORATORY SITE LOCATED AT 320 WAKARA WAY| SALT LAKE CITY| UT 84108."|FALSE|TRUE|1|1
4|P140020|S003|BRACANALYSIS CDX|cancer-related germline gene mutation detection system|2015-09-17 00:00:00|2015-11-18 00:00:00|"APPROVAL FOR CLARIFICATIONS TO THE INTENDED USE STATEMENT| AS FOLLOWS:BRACANALYSIS CDX IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION AND CLASSIFICATION OF VARIANTS IN THE PROTEIN CODING REGIONS AND INTRON/EXON BOUNDARIES OF THE BRCA1 AND BRCA2 GENES USING GENOMIC DNA OBTAINED FROM WHOLE BLOOD SPECIMENS COLLECTED IN EDTA. SINGLE NUCLEOTIDE VARIANTS AND SMALL INSERTIONS AND DELETIONS (INDELS) ARE IDENTIFIED BY POLYMERASE CHAIN REACTION (PCR) AND SANGER SEQUENCING. LARGE DELETIONS AND DUPLICATIONS IN BRCA1 AND BRCA2 ARE DETECTED USING MULTIPLEX PCR. RESULTS OF THE TEST ARE USED AS AN AID IN IDENTIFYING OVARIAN CANCER PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA VARIANTS| WHO ARE OR MAY BECOME ELIGIBLE FOR TREATMENT WITH LYNPARZA (OLAPARIB). THIS ASSAY IS FOR PROFESSIONAL USE ONLY AND IS TO BE PERFORMED ONLY AT MYRIAD GENETIC LABORATORIES| A SINGLE LABORATORY SITE LOCATED IN SALT LAKE CITY| UTAH."|FALSE|TRUE|1|1
5|P120022|S020|therascreen EGFR RGQ PCR Kit|somatic gene mutation detection system|2019-08-28 00:00:00|2019-09-26 00:00:00|Approval for updates to the limitations section of the instructions for use to include additional cross-reactivity information for the therascreen EGFR RGQ PCR Kit.|FALSE|TRUE|2|1
6|P120022|S001|THERASCEEN EGFR RGQ PCR KIT|somatic gene mutation detection system|2014-09-18 00:00:00|2015-07-10 00:00:00|"APPROVAL FOR EXTENDING THE LABEL CLAIM OF THE THERASCREEN EGFR RGQ PCR KIT TO INCLUDE AN INDICATION FOR IRESSA (GEFITINIB). THE DEVICE| AS MODIFIED| WILL BE MARKETED UNDER THE TRADE NAME THERASCREEN EGFR RGQ PCR KIT AND IS INDICATED FOR:THE THERASCREEN EGFR RGQ PCR KIT IS A REAL-TIME PCR TEST FOR THE QUALITATIVE DETECTION OF EXON 19 DELETIONS AND EXON 21 (L858R) SUBSTITUTION MUTATIONS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE) NON-SMALL CELL LUNG CANCER (NSCLC) TUMOR TISSUE. THE TEST IS INTENDED TO BE USED TO SELECT PATIENTS WITH NSCLC FOR WHOM GILOTRIF (AFATINIB) OR IRESSA (GEFITINIB)| EGFR TYROSINE KINASE INHIBITORS (TKIS)| IS INDICATED. SAFETY AND EFFICACY OF GILOTRIF (AFATINIB) AND IRESSA (GEFITINIB) HAVE NOT BEEN ESTABLISHED IN THE PATIENTS WHOSE TUMORS HAVE L861Q| G719X| S768I| EXON 20 INSERTIONS| AND T790M MUTATIONS| WHICH ARE ALSO DETECTED BY THE THERASCREEN EGFR RGQ PCR KIT.SPECIMENS ARE PROCESSED USING THE QIAAMP DSP DNA FFPE TISSUE KIT FOR MANUAL SAMPLE PREPARATION AND THE ROTOR-GENE Q MDX INSTRUMENT FOR AUTOMATED AMPLIFICATION AND DETECTION."|FALSE|TRUE|2|1
7|P120022|S022|therascreen EGFR RGQ PCR Kit|somatic gene mutation detection system|2020-10-23 00:00:00|2021-07-07 00:00:00|Approval for incorporation of a lower boundary for the therascreen EGFR RGQ PCR assay Ct cutoff range and an update to the software and handbook to address this change. |FALSE|TRUE|2|1
8|P120022|S007|THERASCREEN EGFR RGQ PCR KIT|somatic gene mutation detection system|2015-01-21 00:00:00|2015-02-19 00:00:00|"CHANGE OF FILLING PROCESS FOR PROTEINASE K IN THE QIAAMP DSP DNA FFPE TISSUE KIT FROM A MANUAL TO AN AUTOMATED PROCESS AT THE HILDEN| GERMANY FACILITY."|FALSE|TRUE|2|1
9|P120022|S019|therascreen EGFR RGQ PCR Kit|somatic gene mutation detection system|2018-03-08 00:00:00|2018-04-06 00:00:00|Change the supplier and the polymer used for a kit consumable.|FALSE|TRUE|2|1
10|P120022|S008|QIAGEN THERASCREEN EGFR RGQ PCR KIT|somatic gene mutation detection system|2015-01-26 00:00:00|2015-04-23 00:00:00|APPROVAL FOR REPLACEMENT OF LYSIS TUBE IN THE QIAAMP DSP DNA FFPE TISSUE KIT.|FALSE|TRUE|2|1
11|P120022|S015|"Therascreen EGFR| RGQ| PCR Kit"|somatic gene mutation detection system|2017-06-29 00:00:00|2017-07-24 00:00:00|Improvement to the therascreen EFGR Kit stock Internal Control (IC) Mix manufacturing process.|FALSE|TRUE|2|1
12|P120022|S002|THERASCREEN EGFR RGQ PCR KIT|somatic gene mutation detection system|2014-11-19 00:00:00|2014-12-19 00:00:00|CHANGE TO THE MANUFACTURING METHOD OF THE POSITIVE CONTROL (PC) IN THE EGFR RGQ PCR KIT. THE CHANGE IN MANUFACTURING METHOD INCLUDES AN ADJUSTMENT STEP OF AN IN-PROCESS PROCEDURE TO ENSURE THAT TARGETED AMOUNTS OF EACH OLIGONUCLEOTIDE WITHIN THE PC ARE CALCULATED TO ACHIEVE THE TARGET CROSSING THRESHOLD (CT).|FALSE|TRUE|2|1
13|P120022|S009|QIAGEN THERASCREEN EGFR RGQ PCR KIT|somatic gene mutation detection system|2015-01-26 00:00:00|2015-04-24 00:00:00|APPROVAL FOR REPLACEMENT OF THE RAW MATERIALS USED IN MANUFACTURING OF PRIMARY PACKAGING (BOTTLES AND CAPS) FOR BUFFERS IN THE QIAAMP DSP DNA FFPE TISSUE KIT.|FALSE|TRUE|2|1
14|P120022|S013|THERASCREEN EGFR RGQ PCR KIT|somatic gene mutation detection system|2016-08-10 00:00:00|2016-09-07 00:00:00|Change to the mean Ct specification for the positive control (PC) at the final kit release stage and the target Ct value for the manufacturing adjustment process for the L861Q reaction mix.|FALSE|TRUE|2|1
15|P120022||THERASCREEN EGFR RGQ PCR KIT|somatic gene mutation detection system|2012-11-30 00:00:00|2013-07-12 00:00:00|"APPROVAL FOR THE THERASCREEN EGFR RGQ PCR KIT. THIS DEVICE IS INDICATED FOR: THE THERASCREEN EGFR RGQ PCR KIT IS A REAL-TIME PCR TEST FOR THE QUALITATIVE DETECTION OF EXON 19 DELETIONS AND EXON 21 (L858R) SUBSTITUTION MUTATIONS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE) NONSMALL CELL LUNG CANCER (NSCLC) TUMOR TISSUE. THE TEST IS INTENDED TO BE USED TO SELECT PATIENTS WITH NSCLC FOR WHOM GILOTRJF (AFATINIB)| AN EGFR TYROSINE KINASE INHIBITOR (TKI)| IS INDICATED. SAFETY AND EFFICACY OF GILOTRIF (AFATINIB) HAVE NOT BEEN ESTABLISHED IN PATIENTS WHOSE TUMORS HAVE L861Q| G719X| 87681| EXON 20 INSERTIONS| AND T790M MUTATIONS| WHICH ARE ALSO DETECTED BY THE THERASCREEN EGFR RGQ PCR KIT. SPECIMENS ARE PROCESSED USING THE QIAAMP DSP DNA FFPE TISSUE KIT FOR MANUAL SAMPLE PREPARATION AND THE ROTOR-GENE Q MDX INSTRUMENT FOR AUTOMATED AMPLIFICATION ANDDETECTION."|FALSE|TRUE|2|1
16|P120022|S005|THERASCREEN EGFR RGQ PCR KIT|somatic gene mutation detection system|2014-12-22 00:00:00|2015-01-16 00:00:00|CHANGE TO THE SUPPLIER¿S PURITY TESTING METHOD FOR THE INTERNAL CONTROL TEMPLATE IN YOUR THERASCREEN EGFR RGQ PCR KIT. THE NEW PURITY TESTING WILL USE REVERSED PHASE-ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY (RP-UPLC) WITH A CHANGE IN ACCEPTANCE CRITERION FROM >=90% TO >=80%.|FALSE|TRUE|2|1
17|P120022|S016|Therascreen EGFR RGQ PCR Kit|somatic gene mutation detection system|2017-07-28 00:00:00|2018-01-12 00:00:00|"Approval for extending the labeling claim of the therascreen EGFR RGQ PCR Kit to include detection of EGFR mutations L861Q| G719X and S768I| to aid in identifying patients with NSCLC for whom safety and efficacy of GILOTRIF (afatininb) has been established."|FALSE|TRUE|2|1
18|P120022|S018|therascreen EGFR RGQ PCR Kit|somatic gene mutation detection system|2018-02-16 00:00:00|2018-09-27 00:00:00|Approval for to extend the intended use of the therascreen EGFR RGQ PCR Kit to include the selection of patients with NSCLC for whom dacomitinib is indicated.|FALSE|TRUE|2|1
19|P120019|S019|"Cobas EGFR Mutation Test v2| Cobas DNA and cfDNA Sample Preparation Kit"|somatic gene mutation detection system|2018-02-23 00:00:00|2018-08-22 00:00:00|"Approval for the cobas EGFR Mutation Test v2. The device is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anti-coagulated peripheral whole blood.The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 below in accordance with the approved therapeutic product labeling:Table 1Drug FFPET PlasmaTARCEVA (erlotinib) Exon 19 deletions and L858R Exon 19 deletions and L858RTAGRISSO (osimertinib) Exon 19 deletions| L858R and T790M Exon 19 deletions| L858R and T790M* IRESSA (gefitinib) Exon 19 deletions and L858R Exon 19 deletions and L858RPatients with positive cobas EGFR Mutation Test v2 test results using plasma specimens for the presence of the EGFR mutations listed above are eligible for treatment with the corresponding drug as indicated in Table 1 (see Note* for T790M). Patients who are negative for these mutations by this test using plasma specimens should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type.Note: *The efficacy of TAGRISSO (osimertinib) has not been established in the EGFR T790M plasma-positive| tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Drug safety and efficacy have not been established for the following EGFR mutations also detected by the cobas EGFR Mutation Test v2:Table 2Drug FFPET PlasmaTARCEVA (erlotinib) G719X| Exon 20 insertions| T790M| S768I and L861Q G719X| Exon 20 insertions| T790M| S768I and L861QTAGRISSO (osimertinib) G719X| Exon 20 insertions| S768I| and L861Q G719X| Exon 20 insertions| S768I| and L861QIRESSA (gefitinib) G719X| Exon 20 insertions| T790M| S768I and L861Q G719X| Exon 20 insertions| T790M| S768I and L861QFor manual sample preparation| FFPET specimens are processed using the cobas DNA Sample Preparation Kit and plasma specimens are processed using the cobas cfDNA Sample Preparation Kit. The cobas z 480 analyzer is used for automated amplification and detection."|FALSE|TRUE|3|1
20|P120019|S018|cobas EGFR Mutation Test v2|somatic gene mutation detection system|2017-11-30 00:00:00|2018-04-18 00:00:00|"The cobas EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anti-coagulated peripheral whole blood.The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 below in accordance with the approved therapeutic product labeling:Table 1 Drug FFPET PlasmaTARCEVA (erlotinib) Exon 19 deletions and L858R Exon 19 deletions and L858RTAGRISSO (osimertinib) Exon 19 deletions| L858R and T790M Exon 19 deletions| L858R and T790M*Patients with positive cobas EGFR Mutation Test v2 test results using plasma specimens for the presence of the EGFR mutations listed above are eligible for treatment with the corresponding drug as indicated in Table 1 (see Note* for T790M). Patients who are negative for these mutations by this test using plasma specimens should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type.*The efficacy of TAGRISSO (osimertinib) has not been established in the EGFR T790M plasma-positive| tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained. Drug safety and efficacy have not been established for the following EGFR mutations also detected by the cobas EGFR Mutation Test v2: Table 2 Drug FFPET Plasma TARCEVA (erlotinib) G719X| Exon 20 insertions| T790M| S768I and L861Q G719X| Exon 20 insertions| T790M| S768I and L861Q TAGRISSO (osimertinib) G719X| Exon 20 insertions| S768I| and L861Q G719X| Exon 20 insertions| S768I| and L861QFor manual sample preparation| FFPET specimens are processed using the cobas DNA Sample Preparation Kit and plasma specimens are processed using the cobas cfDNA Sample Preparation Kit. The cobas z 480 analyzer is used for automated amplification and detection."|FALSE|TRUE|3|1
21|P120019|S016|cobas EGFR Mutation Test v2|somatic gene mutation detection system|2017-10-27 00:00:00|2018-04-18 00:00:00|"Approval of the cobas EGFR Mutation Test v2. The device is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anti-coagulated peripheral whole blood. The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 below in accordance with the approved therapeutic product labeling:Table 1Drug FFPET PlasmaTARCEVA (erlotinib) Exon 19 deletions and L858R Exon 19 deletions and L858RTAGRISSO (osimertinib) Exon 19 deletions| L858R| and T790M T790M*Patients with positive cobas EGFR Mutation Test v2 test results using plasma specimens for the presence of the EGFR mutations listed above are eligible for treatment with the corresponding drug as indicated in Table 1 (see Note* for T790M). Patients who are negative for these mutations by this test using plasma specimens should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type.*The efficacy of TAGRISSO (osimertinib) has not been established in the EGFR T790M plasma-positive| tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Drug safety and efficacy have not been established for the following EGFR mutations also detected by the cobas EGFR Mutation Test v2. Table 2Drug FFPET PlasmaTARCEVA (erlotinib) G719X| Exon 20 insertions| T790M| S768I| and L861Q G719X| Exon 20 insertions| T790M| S768I| and L861QTAGRISSO (osimertinib) G719X| Exon 20 insertions| S768I| and L861Q G719X| Exon 19 deletions| L858R| Exon 20 insertions| S768I| and L861QFor manual sample preparation| FFPET specimens are processed using the cobas DNA Sample Preparation Kit and plasma specimens are processed using the cobas cfDNA Sample Preparation Kit. The cobas z 480 analyzer is used for automated amplification and detection."|FALSE|TRUE|3|1
22|P120019|S022|"cobas EGFR Mutation Test| V2.0"|somatic gene mutation detection system|2018-06-08 00:00:00|2018-07-05 00:00:00|Eliminate a duplicative in-process test for designated kit reagents.|FALSE|TRUE|3|1
23|P120019|S004|COBAS EGFR MUTATION TEST|somatic gene mutation detection system|2013-12-13 00:00:00|2014-03-12 00:00:00|APPROVAL FOR CHANGES TO THE COBAS 4800 SR2 SYSTEM SOFTWARE ARCHITECTURE AND ASSAY SPECIFIC ANALYSIS PACKAGE (ASAP) SOFTWARE FOR THE COBAS BRAF V600 MUTATION TEST AND COBAS EGFR MUTATION TEST.|FALSE|TRUE|3|1
24|P120019|S007|COBAS EGFR MUTATION TEST V2|somatic gene mutation detection system|2015-05-28 00:00:00|2015-11-13 00:00:00|"APPROVAL FOR THE COBAS EGFR MUTATION TEST V2. THIS DEVICE IS INDICATED FOR:THE COBAS EGFR MUTATION TEST V2 IS A REAL-TIME PCR TEST FOR THE QUALITATIVE DETECTION OF DEFINED MUTATIONS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED TUMOR TISSUE (FFPET) FROM NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS. THE TEST IS INTENDED TO AID IN IDENTIFYING PATIENTS WITH NSCLC WHOSE TUMORS HAVE DEFINED EGFR MUTATIONS AND FOR WHOM SAFETY AND EFFICACY OF A DRUG HAVE BEEN ESTABLISHED AS FOLLOWS: TARCEVA (ERLOTINIB)/EXON 19 DELETIONS AND L858R AND TAGRISSO (OSIMERTINIB) T790M. DRUG SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED FOR THE FOLLOWING EGFR MUTATIONS ALSO DETECTED BY THE COBAS EGFR MUTATION TEST V2: TARCEVA (ERLOTINIB)/G719X| EXON 20 INSERTIONS| T790M| S768I AND L861Q/TAGRISSO (OSIMERTINIB)/G719X| EXON 19 DELETIONS| L858R| EXON 20 INSERTIONS| S768I| AND L861Q. FOR MANUAL SAMPLE PREPARATION| FFPET SPECIMENS ARE PROCESSED USING THE COBAS DNA SAMPLE PREPARATION KIT AND THE COBAS Z 480 ANALYZER IS USED FOR AUTOMATED AMPLIFICATION AND DETECTION. "|FALSE|TRUE|3|1
25|P120019|S031|cobas EGFR Mutation Test v2|somatic gene mutation detection system|2020-04-30 00:00:00|2020-10-27 00:00:00|Approval for cobas EGFR Mutation Test v2 label expansion to obtain companion diagnostic group labeling claim for EGFR Tyrosine Kinase Inhibitors (TKI) for specific EGFR mutations detected by the test.|FALSE|TRUE|3|1
26|P120019||COBAS EGFR MUTATION TEST|somatic gene mutation detection system|2012-11-08 00:00:00|2013-05-14 00:00:00|"APPROVAL FOR THE COBAS EGFR MUTATION TEST. THE COBAS EGFR MUTATION TEST IS A REAL-TIME PCR TEST FOR THE QUALITATIVE DETECTION OF EXON 19 DELETIONS AND EXON 21 (L858R) SUBSTITUTION MUTATIONS OFTHE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPET) HUMAN NON-SMALL CELL LUNG CANCER (NSCLC) TUMOR TISSUE. THE TEST IS INTENDED TO BE USED AS AN AID IN SELECTING PATIENTS WITH METASTATIC NSCLC FOR WHOM TARCEVA (ERLOTINIB)| AN EGFR TYROSINE KINASE INHIBITOR (TK1)| IS INDICATED. SPECIMENS ARE PROCESSED USING THE COBAS DNA SAMPLE PREPARATION KIT FOR MANUAL SAMPLE PREPARATION AND THE COBAS Z 480 ANALYZER FOR AUTOMATED AMPLIFICATION AND DETECTION."|FALSE|TRUE|3|1
27|P120019|S029|cobas EGFR Mutation Test v2|somatic gene mutation detection system|2019-06-27 00:00:00|2019-09-25 00:00:00|Approval for a formulation change to the cobas DNA Sample Preparation Kit used with the cobas EGFR Mutation Test for plasma and tissues specimens.|FALSE|TRUE|3|1
28|P170041|S002|Abbott RealTime IDH1 Assay|somatic gene mutation detection system|2019-10-16 00:00:00|2019-11-12 00:00:00|Update of Quality Procedures for Amplification Reagent Kit and Control Kit. |FALSE|TRUE|5|1
29|P170041|S001|RealTime IDH1|somatic gene mutation detection system|2019-08-29 00:00:00|2019-09-24 00:00:00|Additional internal QC testing for the DNA Sample Preparation Kit.|FALSE|TRUE|5|1
30|P170041||Abbott RealTime IDH1|somatic gene mutation detection system|2017-12-05 00:00:00|2018-07-20 00:00:00|"Approval for the Abbott RealTime IDH1. Abbott RealTime IDH1 is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs) coding five IDH1 R132 mutations (R132C| R132H| R132G| R132S| and R132L) in DNA extracted from human blood (EDTA) or bone marrow (EDTA). Abbott RealTime IDH1 is for use with the Abbott m2000rt System.Abbott RealTime IDH1 is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-1 (IDH1) mutation for treatment with TIBSOVO (ivosidenib). This test is for prescription use only."|FALSE|TRUE|5|1
31|P170019|S004|FoundationOne CDx|"next generation sequencing oncology panel| somatic or germline variant detection system"|2018-09-24 00:00:00|2019-07-01 00:00:00|Approval order for extending the label claim to include an indication for LYNPARZA (olaparib) in ovarian cancer patients with BRCA1/2 alterations.|FALSE|TRUE|7|1
32|P170019|S017|FoundationOne CDx (F1CDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-01-31 00:00:00|2020-10-23 00:00:00|Approval order to expand the intended use of FoundationOneCDx (F1CDx) to include NTRK1/2/3 fusions in patients with solid tumors who may benefit from treatment with VITRAKVI (larotrectinib).|FALSE|TRUE|7|1
33|P170019|S016|FoundationOne CDx (F1CDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-01-21 00:00:00|2020-06-16 00:00:00|Approval order to expand the intended use of FoundationOneCDx (F1CDx) to include high tumor mutational burden (TMB) at the cut-off of greater than or equal to 10 mutations per megabase (mut/Mb) in patients with solid tumors who may benefit from treatment with KEYTRUDA (pembrolizumab).|FALSE|TRUE|7|1
34|P170019|S022|"FoundationOne CDx| FoundationOne Liquid CDx"|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-11-27 00:00:00|2021-07-21 00:00:00|"Approval for the variant classification procedure to add additional variants to existing BRCA1| BRCA2 and ATM companion diagnostic claims for PARP inhibitors (e.g.| rucaparib and olaparib) on FoundationOne CDx and FoundationOne Liquid CDx"|FALSE|TRUE|7|1
35|P170019|S023|FoundationOne CDx (F1CDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-12-01 00:00:00|2021-06-30 00:00:00|Approval for Expanding the indications for use to include a CDx indication for detecting ALK rearrangements in non-small cell lung cancer patients who may be candidates for brigatinib treatment.|FALSE|TRUE|7|1
36|P170019|S011|FoundationOne CDx (F1CDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2019-10-17 00:00:00|2020-05-06 00:00:00|Approval to include a companion diagnostic indication for detection of MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping in non-small cell lung cancer patients who may benefit from treatment with TABRECTA (capmatinib).|FALSE|TRUE|7|1
37|P170019|S008|FoundationOne CDx (F1CDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2019-04-09 00:00:00|2019-07-01 00:00:00|Approval order for extending the label claim to include an indication for TAGRISSO (osimertinib) in non-small cell lung cancer patients with EGFR exon 19 deletions and EGFR exon 21 L858R alterations. |FALSE|TRUE|7|1
38|P170019|S021|FoundationOne CDx (F1CDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-10-29 00:00:00|2021-05-28 00:00:00|Approval to expand the intended use of FoundationOne CDx (F1CDx) to include a companion diagnostic indication for FGFR2 fusion/rearrangements in patients with Cholangiocarcinoma who may benefit from treatment with Truseltiq (infigratinib).|FALSE|TRUE|7|1
39|P170019|S013|FoundationOne CDx (F1CDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2019-10-31 00:00:00|2020-04-17 00:00:00|Approval order for extending the label claim to include an indication for PEMAZYRE(pemigatinib)in cholangiocarcinoma patients with FGFR2 fusions and select rearrangements. |FALSE|TRUE|7|1
40|P170019|S025|FoundationOne CDx|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-12-28 00:00:00|2021-11-10 00:00:00|Approval for the FoundationOne CDx. The device is intended use is expanded to grant companion diagnostic group labeling claims for melanoma patients harboring BRAF V600E alterations for BRAF inhibitor monotherapy group claim and for BRAF V600E or V600K alterations for BRAF/MEK inhibitor combination group claim. |FALSE|TRUE|7|1
41|P170019||FoundationOne CDx|"next generation sequencing oncology panel| somatic or germline variant detection system"|2017-06-02 00:00:00|2017-11-30 00:00:00|"Approval for the FoundationOne CDx (F1CDx). This device is a next generation sequencing based in vitro diagnostic device for detection of substitutions| insertion and deletion alterations (indels)| and copy number alterations (CNAs) in 324 genes and select gene rearrangements| as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally| F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. The F1CDx assay is a single-site assay performed at Foundation Medicine| Inc.Table 1: Companion diagnostic indicationsIndication: Non-small cell lung cancer (NSCLC). - Biomarker: EGFR exon 19 deletions and EGFR exon 21 L858R alterations. Therapy: Gilotrif (afatinib)| Iressa (gefitinib)| or Tarceva (erlotinib). - Biomarker: EGFR exon 20 T790M alterations. Therapy: Tagrisso (osimertinib). - Biomarker: ALK rearrangements. Therapy: Alecensa (alectinib)| Xalkori (crizotinib)| or Zykadia (ceritinib). - Biomarker: BRAF V600E. Therapy: Tafinlar (dabrafenib) in combination with Mekinist (trametinib).Indication: Melanoma. - Biomarker: BRAF V600E. Therapy: Tafinlar (dabrafenib) or Zelboraf (vemurafenib) - Biomarker: BRAF V600E and V600K. Therapy: Mekinist (trametinib) or Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib).Indication: Breast cancer. Biomarker: ERBB2 (HER2) amplification. Therapy: Herceptin (trastuzumab)| Kadcyla (ado-trastuzumab-emtansine)| orPerjeta (pertuzumab).Indication: Colorectal cancer. - Biomarker: KRAS wild-type (absence of mutations in codons 12 and 13). Therapy: Erbitux (cetuximab) - Biomarker: KRAS wild-type (absence of mutations in exons 2| 3| and 4) and NRAS wild type (absence of mutations in exons 2| 3| and 4). Therapy: Vectibix (panitumumab)Indication: Ovarian cancer. Biomarker: BRCA1/2 alterations. Therapy: Rubraca (rucaparib)"|FALSE|TRUE|7|1
42|P170019|S030|FoundationOne CDx (F1CDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2021-07-01 00:00:00|2022-01-19 00:00:00|"Approval to expand the intended use of FoundationOne CDx (F1CDx) to expand the intended use of FoundationOne CDx (F1CDx) to include a companion diagnostic indication for identifying patients with BRAF V600 mutation-positive unresectable or metastatic melanoma| who may benefit from treatment with atezolizumab (Tecentriq) in combination with cobimetinib and vemurafenib."|FALSE|TRUE|7|1
43|P170019|S006|FoundationOne CDx|"next generation sequencing oncology panel| somatic or germline variant detection system"|2018-12-26 00:00:00|2019-12-03 00:00:00|"Approval order for extending the label claim to include an indication for PIQRAY (alpelisib) in breast cancer patients with PIK3CA C420R| E542K| E545A| E545D [1635G>T only]| E545G| E545K| Q546E| Q546R| H1047L| H1047R| and H1047Y alterations. "|FALSE|TRUE|7|1
44|P170019|S033|FoundationOne CDx (FICDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2021-12-23 00:00:00|2022-03-16 00:00:00|Approval for FoundationOne CDx (FICDx) label expansion to obtain companion diagnostic group labeling claim for non-small cell lung cancer patients harboring EGFR exon 19 deletions or EGFR exon 21 L858R mutations for treatment with any one of the FDA-approved EGFR Tyrosine Kinase Inhibitors (TKI).|FALSE|TRUE|7|1
45|P140025||VENTANA ALK (D5F3) CDX ASSAY|"immunohistochemistry assay| antibody| anaplastic lymphoma kinase"|2014-11-14 00:00:00|2015-06-12 00:00:00|" APPROVAL FOR THE VENTANA ALK (D5F3) CDX ASSAY. THIS DEVICE IS INDICATED FOR THE FOLLOWING:VENTANA ALK (D5F3) CDX ASSAY IS INTENDED FOR THE QUALITATIVE DETECTION OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) PROTEIN IN FORMALIN-FIXED| PARAFFIN-EMBEDDED (FFPE) NON-SMALL CELL LUNG CARCINOMA (NSCLC) TISSUE STAINED WITH A BENCHMARK XT AUTOMATED STAINING INSTRUMENT. IT IS INDICATED AS AN AID IN IDENTIFYING PATIENTS ELIGIBLE FOR TREATMENT WITH XALKORI (CRIZOTINIB)."|FALSE|TRUE|8|1
46|P140025|S003|VENTANA ALK (D5F3) CDX ASSAY|"immunohistochemistry assay| antibody| anaplastic lymphoma kinase"|2016-03-22 00:00:00|2016-10-21 00:00:00|Approval for adding the BenchMark ULTRA instrument to the intended use and labeling for the VENTANA ALK (D5F3) CDx Assay|FALSE|TRUE|8|1
47|P140025|S014|VENTANA ALK (D5F3) CDx Assay|"immunohistochemistry assay| antibody| anaplastic lymphoma kinase"|2020-11-16 00:00:00|2021-03-03 00:00:00|"Approval for inclusion of an indication for LORBRENA ((lorlatinib). The device will be marketed under the trade name VENTANA ALK (D5F3) CDx Assay and is indicated for:VENTANA ALK (D5F3) CDx Assay is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed| paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue stained with a BenchMark XT or BenchMark ULTRA automated staining instrument. It is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib)| ZYKADIA (ceritinib)| or ALECENSA (alectinib) or LORBRENA (lorlatinib).This product should be interpreted by a qualified pathologist in conjunction with histological examination| relevant clinical information| and proper controls.This product is intended for in vitro diagnostic (IVD) use."|FALSE|TRUE|8|1
48|P140025|S005|VENTANA ALK (D5F3) CDX ASSAY|"immunohistochemistry assay| antibody| anaplastic lymphoma kinase"|2016-12-28 00:00:00|2017-05-26 00:00:00|Approval for extending the label claim of the VENTANA ALK (D5F3) CDx Assay to include an indication for Zykadia (ceritinib)|FALSE|TRUE|8|1
49|P140025|S006|VENTANA ALK (D5F3) CDx Assay|"immunohistochemistry assay| antibody| anaplastic lymphoma kinase"|2017-06-07 00:00:00|2017-11-06 00:00:00|"Approval for the VENTANA ALK (D5F3) CDx Assay. The device is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed| paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue stained with a BenchMark XT or BenchMark ULTRA automated staining instrument. It is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib) or ZYKADIA (ceritinib) or ALECENSA (alectinib)."|FALSE|TRUE|8|1
50|P170005||Abbott RealTime IDH2|somatic gene mutation detection system|2017-02-02 00:00:00|2017-08-01 00:00:00|"Approval for the Abbott RealTime IDH2. The device is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs) coding nine IDH2 mutations (R140Q| R140L| R140G| R140W| R172K| R172M| R172G| R172S| and R172W) in DNA extracted from blood (EDTA) or human bone marrow (EDTA). Abbott RealTime IDH2 is for use with the Abbott m2000rt System.Abbott RealTime IDH2 is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-2 (IDH2) mutation for treatment with IDHIFA (enasidenib)."|FALSE|TRUE|9|1
51|P170005|S001|RealTime IDH2|somatic gene mutation detection system|2019-08-29 00:00:00|2019-09-24 00:00:00|Additional internal QC testing for the DNA Sample Preparation Kit.|FALSE|TRUE|9|1
52|P160038||Praxis Extended RAS Panel|"next generation sequencing oncology panel| somatic or germline variant detection system"|2016-09-02 00:00:00|2017-06-29 00:00:00|"Approval for the Praxis Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2| 3| and 4) and NRAS (exons 2| 3| and 4)] in DNA extracted from formalin-fixed| paraffin-embedded (FFPE) colorectal cancer (CRC) tissue samples. The Praxis™ Extended RAS Panel is indicated to aid in the identification of patients with colorectal cancer for treatment with Vectibix (panitumumab) based on a no mutation detected test result. The test is intended to be used on the Illumina MiSeqDx instrument."|FALSE|TRUE|10|1
53|P160045|S028|Oncomine™ Dx Target Test|"next generation sequencing oncology panel| somatic or germline variant detection system"|2021-03-02 00:00:00|2021-08-25 00:00:00|Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of single nucleotide variants in IDH1 in cholangiocarcinoma patients who may benefit from treatment with TIBSOVO (ivosidenib).|FALSE|TRUE|11|1
54|P160045||Oncomine Dx Target Test|"next generation sequencing oncology panel| somatic or germline variant detection system"|2016-10-17 00:00:00|2017-06-22 00:00:00|"Approval for the The Oncomine Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high throughput| parallel-sequencing technology to detect single nucleotide variants (SNVs) and deletions in 23 genes from DNA and fusions in ROS1 from RNA isolated from formalin-fixed| paraffin-embedded (FFPE) tumor tissue samples from patients with non-small cell lung cancer (NSCLC) using the Ion PGM Dx System. The test is indicated to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling.Table 1. List of variants for therapeutic useGene Variant Targeted therapyBRAF BRAF V600E TAFINLAR (dabrafenib) in combination with MEKINIST (trametinib)ROS1 ROS1 fusions XALKORI (crizotinib)EGFR L858R| Exon 19 deletions IRESSA (gefitinib)Safe and effective use has not been established for selecting therapies using this device for the variants in Table 1 in tissue types other than NSCLC.Results other than those listed in Table 1 are indicated for use only in patients who have already been considered for all appropriate therapies (including those listed in Table 1). Analytical performance using NSCLC specimens has been established for the variants listed in Table 2.Table 2. List of variants with established analytical performance onlyGene Variant ID Nucleotide changeKRAS COSM512 c.34_35delGGinsTTKRAS COSM516 c.34G>TMET COSM707 c.3029C>TPIK3CA COSM754 c.1035T>AThe test is not indicated to be used for standalone diagnostic purposes| screening| monitoring| risk assessment| or prognosis."|FALSE|TRUE|11|1
55|P160045|S019|Oncomine Dx Target Test|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-04-01 00:00:00|2020-09-04 00:00:00|Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of RET fusions in non-small cell lung cancer patients who may benefit from treatment with GAVRETO (pralsetinib).|FALSE|TRUE|11|1
56|P160045|S027|Oncomine™ Dx Target Test|"next generation sequencing oncology panel| somatic or germline variant detection system"|2021-02-22 00:00:00|2021-12-01 00:00:00|Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of EGFR exon 20 insertion mutations in non-small cell lung cancer patients who may benefit from treatment with RYBREVANT (amivantamab-vmjw).|FALSE|TRUE|11|1
57|P160045|S029|Oncomine Dx Target Test (ODxT Test)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2021-05-03 00:00:00|2021-09-15 00:00:00|Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of EGFR exon 20 insertion mutations in non-small cell lung cancer patients who may benefit from the treatment with EXKIVITY (mobocertinib).|FALSE|TRUE|11|1
58|P160045|S018|Oncomine Dx Target Test|"next generation sequencing oncology panel| somatic or germline variant detection system"|2019-10-16 00:00:00|2019-11-13 00:00:00|New PCR tube is provided with the kit.|FALSE|TRUE|11|1
59|P160045|S034|Oncomine Dx Target Test|"next generation sequencing oncology panel| somatic or germline variant detection system"|2021-12-23 00:00:00|2022-01-21 00:00:00|"Approval of the clinical protocol titled Oncomine Dx Target Test Clinical Validation Protocol: Biomarker EGFR Exon 20 Insertions (Olympic) - PRJ0002127 Supplemental Sample Study| for the post-approval study (PAS) protocol."|FALSE|TRUE|11|1
60|P160040|S002|LeukoStrat CDx FLT3 Mutation Assay|somatic gene mutation detection system|2018-03-30 00:00:00|2018-11-28 00:00:00|"Approval for the LeukoStrat CDx FLT3 Mutation Assay. The device is a PCR-based in vitro diagnostic test designed to detect internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML).The LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the selection of patients with AML for whom RYDAPT (midostaurin) treatment is being considered.The LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the selection of patients with AML for whom XOSPATA (gilteritinib) treatment is being considered.The LeukoStrat CDx FLT3 Mutation Assay is to be performed only at Laboratory for Personalized Molecular Medicine (LabPMM) LLC| a single laboratory site| located at 10222 Barnes Canyon Rd.| Bldg. 1| San Diego| CA 92121."|FALSE|TRUE|12|1
61|P160040|S004|LeukoStrat CDx FLT3 Mutation Assay|somatic gene mutation detection system|2018-11-06 00:00:00|2018-12-21 00:00:00|"Approval for the LeukoStrat CDx FLT3 Mutation Assay. The device is a PCR-based in vitro diagnostic test designed to detect internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML). The LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the selection of patients with AML for whom RYDAPT (midostaurin) treatment is being considered. The LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the selection of patients with AML for whom XOSPATA (gilteritinib) treatment is being considered. The LeukoStrat CDx FLT3 Mutation Assay is to be performed only at Laboratory for Personalized Molecular Medicine (LabPMM) LLC| a single laboratory site| located at 10222 Barnes Canyon Rd.| Bldg. 1| San Diego| CA 92121."|FALSE|TRUE|12|1
62|P160040|S006|LeukoStrat CDx FLT3 Mutation Assay|somatic gene mutation detection system|2019-10-17 00:00:00|2020-05-14 00:00:00|"Approval for distribution of the Leukostrat CDx FLT3 Mutation Assay on the 3500xL Dx Genetic Analyzer Instrument. The device| as modified| will be marketed under the trade name LeukoStrat CDx FLT3 Mutation Assay and is indicated for:The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based in vitro diagnostic test designed to detect internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML).The LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the assessment of patients with AML for whom RYDAPT (midostaurin) treatment is being considered.The LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the assessment of patients with AML for whom XOSPATA (gilteritinib) treatment is being considered.The test is for use on the 3500xL Dx Genetic Analyzer."|FALSE|TRUE|12|1
63|P160040|S007|LeukoStrat CDx FLT3 Mutation Assay|somatic gene mutation detection system|2020-12-02 00:00:00|2021-08-26 00:00:00|Approval for the improvement of the manufacturing method for the FLT3 TKD Positive Control included with the LeukoStrat CDx FLT3 Mutation Assay.|FALSE|TRUE|12|1
64|P160040|S008|LeukoStrat CDx FLT3 Mutation Assay|somatic gene mutation detection system|2021-07-09 00:00:00|2021-08-05 00:00:00|Approval of changes made to the Instructions for Use of the LeukoStrat CDx FLT3 Mutation Assay. |FALSE|TRUE|12|1
65|P160040|S009|LeukoStrat CDx FLT3 Mutation Assay|somatic gene mutation detection system|2021-07-12 00:00:00|2021-08-11 00:00:00|"Qualification of an automated process for fill| finish| and label the kit components."|FALSE|TRUE|12|1
66|P160040||LeukoStrat CDx FLT3 Mutation Assay|somatic gene mutation detection system|2016-09-02 00:00:00|2017-04-28 00:00:00|"Approval for the LeukoStrat CDx FLT3 Mutation Assay is a PCR-based| in vitro diagnostic test designed to detect internal tandem duplication (ITD) mutations and the tyrosine kinase domain mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML). The LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the selection of patients with AML for whom RYDAPT (midostaurin) treatment is being considered. The Leukostrat CDx FLT3 Mutation Assay is to be performed only at Laboratory for Personalized Molecular Medicine (LabPMM) LLC| a single site laboratory located at 6330 Nancy Ridge Dr.| San Diego| CA 92121."|FALSE|TRUE|12|1
67|P160018||FoundationFocus CDxBRCA|"next generation sequencing oncology panel| somatic or germline variant detection system"|2016-06-30 00:00:00|2016-12-19 00:00:00|"Approval for The FoundationFocus CDxBRCA is a next generation sequencing based in vitro diagnostic device for qualitative detection of BRCA1 and BRCA2 alterations in formalin-fixed paraffin-embedded (FFPE) ovarian tumor tissue. The FoundationFocus CDxBRCA assay detects sequence alterations in BRCA1 and BRCA2 (BRCA1/2) genes. Results of the assay are used as an aid in identifying ovarian cancer patients for whom treatment with Rubraca (rucaparib) is being considered. If a patient is positive for any of the deleterious alterations specified in the BRCA1/2 classification| the patient may be eligible for treatment with Rubraca. This assay is to be performed at Foundation Medicine| Inc.| a single laboratory site located at 150 Second Street| Cambridge| Massachusetts."|FALSE|TRUE|13|1
68|P160018|S001|FoundationFocus CDx BRCA HRD|"next generation sequencing oncology panel| somatic or germline variant detection system"|2017-09-28 00:00:00|2018-04-06 00:00:00|"Approval for the FoundationFocus™ CDx BRCA LOH. The device is an assay that uses next-generation sequencing (NGS) for qualitative detection of BRCA1 and BRCA2 sequence alterations and genomic loss of heterozygosity (LOH) from formalin-fixed| paraffin-embedded (FFPE) ovarian tumor tissue. Results of the test are used as an aid in identifying ovarian cancer patients with deleterious tumor BRCA variants (tBRCA-positive)| who may be eligible for treatment with Rubraca (rucaparib). Positive homologous recombination deficiency (HRD) status (defined as tBRCA-positive or LOH high) in ovarian cancer patients is associated with improved progression-free survival (PFS) from Rubraca (rucaparib) maintenance therapy. See the RUBRACA product label for information about guiding therapy in specific clinical circumstances. This test is to be performed at Foundation Medicine| Inc.| a single laboratory site| located at 150 Second Street| Cambridge| Massachusetts."|FALSE|TRUE|13|1
69|P150041||VYSIS CLL FISH PROBE KIT|"fluorescence in situ hybridization| chromosome 17p deletion (tp53)"|2015-10-30 00:00:00|2016-04-11 00:00:00|The Vysis CLL FISH Probe Kit is a test to detect deletion of the LSI TP53 probe target via fluorescence in situ hybridization (FISH) in peripheral blood specimens from patients with B-cell chronic lymphocytic leukemia (CLL).The test is indicated for detecting deletion of the LSI TP53 probe target (17p-) as an aid in identifying those patients with CLL for whom treatment with VENCLEXTA (venetoclax) is indicated. Vysis CLL FISH Probe Kit is not intended for monitoring of residual disease.|FALSE|TRUE|14|1
70|P150041|S001|Vysis CLL Fish Probe Kit|"fluorescence in situ hybridization| chromosome 17p deletion (tp53)"|2017-11-08 00:00:00|2017-12-06 00:00:00|Vendors relocation of a manufacturing site for production of reagents contained in kit components.|FALSE|TRUE|14|1
71|H140006||KIT D816V ASSAY|somatic gene mutation detection system|2014-11-26 00:00:00|2015-12-18 00:00:00|Approval for the kit d816v mutation detection by pcr for gleevec eligibility in aggressive systemic mastocytosis (asm). Kit d816v mutation detection by pcr for gleevec eligibility in aggressive systemic mastocytosis (asm) (referred to as the ¿kit d816v assay¿) is an in vitro diagnostic test intended for qualitative polymerase chain reaction (pcr) detection of kit d816v mutational status from fresh bone marrow samples of patients with aggressive systemic mastocytosis. The kit d816v mutational assay is indicated as an aid in the selection of asm patients for whom gleevec (imatinib mesylate) treatment is being considered. This assay is for professional use only and is to be performed at a single laboratory site. |FALSE|TRUE|15|1
72|H140005||PDGFRB FISH ASSAY|"fluorescence in situ hybridization| platelet-derived growth factor receptor| beta polypeptide (pdgfrb)| rearrangement"|2014-11-26 00:00:00|2015-12-18 00:00:00|Approval for the pdgfrb fish for gleevec eligibility in myelodysplastic syndrome/myeloproliferative disease (mds/mpd). This device is indicated for the qualitative detection of pdgfrb gene rearrangement from fresh bone marrow samples of patients with mds/mpd with a high index of suspicion based on karyotyping showing a 5q31~33 anomaly. The pdgfrb fish assay is indicated as an aid in the selection of mds/mpd patients for whom gleevec (imatinib mesylate) treatment is being considered. This assay is for professional use only and is to be performed at a single laboratory site. |FALSE|TRUE|16|1
73|P140023|S015|cobas KRAS Mutation Test|somatic gene mutation detection system|2018-06-08 00:00:00|2018-07-05 00:00:00|Eliminate a duplicative in-process test for designated kit reagents.|FALSE|TRUE|17|1
74|P140023|S004|COBAS KRAS MUTATION TEST|somatic gene mutation detection system|2016-02-29 00:00:00|2016-09-24 00:00:00|"The cobas KRAS Mutation Test| for use with the cobas 4800 System| is a real-time PCR test for the detection of mutations in codons 12| 13 and 61 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer (CRC) tumor tissue. The test is intended to be used as an aid in the identification of CRC patients who should not be treated with Erbitux (cetuximab) or with Vectibix (panitumumab) when KRAS Codon 12 or 13 mutation is detected. Safety and efficacy of Erbitux (cetuximab) or Vectibix (panitumumab) have not been established in patients whose tumors have Codon 61 mutation. Specimens are processed using the cobas DNA Sample Preparation Kit for manual sample preparation and the cobas z 480 analyzer for automated amplification and detection."|FALSE|TRUE|17|1
75|P140023|S003|COBAS KRAS MUTATION TEST|somatic gene mutation detection system|2016-01-28 00:00:00|2016-04-25 00:00:00|"Approval for the proposed formulation change (removal of anti-microbial agent ProClin 300) and process changes to production of KRAS reaction Mix| a component of cobas KRAS Mutation Test. "|FALSE|TRUE|17|1
76|P140023||COBAS KRAS MUTATION TEST|somatic gene mutation detection system|2014-10-23 00:00:00|2015-05-07 00:00:00|"APPROVAL FOR THE COBAS KRAS MUTATION TEST. THIS DEVICE IS INDICATED FOR THE FOLLOWING:THE COBAS KRAS MUTATION TEST| FOR USE WITH THE COBAS 4800 SYSTEM| IS A REAL-TIME PCR TEST FOR THE DETECTION OF SEVEN SOMATIC MUTATIONS IN CODONS 12 AND 13 OF THE KRAS GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED HUMAN COLORECTAL CANCER (CRC) TUMOR TISSUE. THE TEST IS INTENDED TO BE USED AS AN AID IN THE IDENTIFICATION OF CRC PATIENTS FOR WHOM TREATMENT WITH ERBITUX (CETUXIMAB) OR WITH VECTIBIX (PANITUMUMAB) MAY BE INDICATED BASED ON A NO MUTATION DETECTED RESULT.SPECIMENS ARE PROCESSED USING THE COBAS DNA SAMPLE PREPARATION KIT FOR MANUAL SAMPLE PREPARATION AND THE COBAS Z 480 ANALYZER FOR AUTOMATED AMPLIFICATION AND DETECTION."|FALSE|TRUE|17|1
77|P140023|S011|Roche cobas KRAS Mutation Test /Roche cobas DNA Sample Preparation Kit|somatic gene mutation detection system|2017-09-27 00:00:00|2017-10-16 00:00:00|Improvement to the shipping and packaging of the cobas KRAS Mutation Test Kit.|FALSE|TRUE|17|1
78|P140023|S022|cobas KRAS Mutation Test|somatic gene mutation detection system|2020-02-18 00:00:00|2020-05-18 00:00:00|Approval for a formulation change to the cobas DNA Sample Preparation Kit used with the cobas KRAS Mutation Test (P140023).|FALSE|TRUE|17|1
79|P110027|S005|THERASCREEN KRAS RGQ PCR KIT|somatic gene mutation detection system|2015-01-21 00:00:00|2015-02-19 00:00:00|"CHANGE OF FILLING PROCESS FOR PROTEINASE K IN THE QIAAMP DSP DNA FFPE TISSUE KIT FROM A MANUAL TO AN AUTOMATED PROCESS AT THE HILDEN| GERMANY FACILITY."|FALSE|TRUE|18|1
80|P110027|S012|therascreen KRAS RGQ PCR KIT|somatic gene mutation detection system|2021-02-10 00:00:00|2021-05-28 00:00:00|Approval for expanding the indication to aid in the identification of non-small cell lung cancer patients whose tumors harbor KRAS G12C mutations and may benefit from treatment with LUMAKRA (sotorasib). |FALSE|TRUE|18|1
81|P110027|S010|therascreen KRAS RGQ PCR Kit|somatic gene mutation detection system|2018-03-08 00:00:00|2018-04-06 00:00:00|Change the supplier and the polymer used for a kit consumable.|FALSE|TRUE|18|1
82|P110027||THERASCREEN KRAS RGQ PCR KIT|somatic gene mutation detection system|2011-07-25 00:00:00|2014-05-23 00:00:00|"APPROVAL FOR THE THERASCREEN KRAS RGQ PCR KIT| WHICH IS TO BE USED AS A COMPANION DIAGNOSTIC FOR THE DRUG VECTIBIX (PANITUMUMAB). THIS DEVICE IS INDICATED FOR:THE THERASCREEN KRAS RGQ PCR KIT IS A REAL-TIME QUALITATIVE PCR ASSAY USED ON THE ROTOR-GENE Q MDX INSTRUMENT FOR THE DETECTION OF SEVEN SOMATIC MUTATIONS IN THE HUMAN KRAS ONCOGENE| USING DNA EXTRACTED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE)| COLORECTAL CANCER (CRC) TISSUE. THE THERASCREEN KRAS RGQ PCR KIT IS INTENDED TO AID IN THE IDENTIFICATION OF CRC PATIENTS FOR TREATMENT WITH ERBITUX (CETUXIMAB) AND VECTIBIX (PANITUMUMAB) BASED ON A KRAS NO MUTATION DETECTED TEST RESULT."|FALSE|TRUE|18|1
83|P110027|S003|THERASCREEN KRAS RGQ PCR KIT|somatic gene mutation detection system|2014-12-22 00:00:00|2015-01-16 00:00:00|CHANGE TO THE SUPPLIERS PURITY TESTING METHOD FOR THE INTERNAL CONTROL TEMPLATE IN YOUR THERASCREEN KRAS RGQ PCR KIT. THE NEW PURITY TESTING WILL USE REVERSED PHASE-ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY (RP-UPLC) WITH A CHANGE IN ACCEPTANCE CRITERION FROM >=90% TO >=80%.|FALSE|TRUE|18|1
84|P110027|S007|QIAGEN THERASCREEN KRAS RGQ PCR KIT|somatic gene mutation detection system|2015-01-26 00:00:00|2015-04-24 00:00:00|APPROVAL FOR REPLACEMENT OF THE RAW MATERIALS USED IN MANUFACTURING OF PRIMARY PACKAGING (BOTTLES AND CAPS) FOR BUFFERS IN THE QIAAMP DSP DNA FFPE TISSUE KIT.|FALSE|TRUE|18|1
85|P110027|S006|QIAGEN THERASCREEN KRAS RGQ PCR KIT|somatic gene mutation detection system|2015-01-26 00:00:00|2015-04-23 00:00:00|APPROVAL FOR REPLACEMENT OF LYSIS TUBE IN THE QIAAMP DSP DNA FFPE TISSUE KIT.|FALSE|TRUE|18|1
86|P030044|S001|DAKOCYTOMATION EGFR PHARMDX KIT|"immunohistochemistry assay| antibody| epidermal growth factor receptor"|2005-11-17 00:00:00|2006-02-01 00:00:00|"APPROVAL FOR ADDITIONAL LABELING CHANGES INCLUDE A CLARIFICATION IN THE DEFINITION OF POSITIVE STAINING FOR INDIVIDUAL TUMOR CELLS| INCLUSION OF LIMITATION ABOUT CETUXIMAB RESPONSE RATE FOR NEGATIVE/ POSITIVE PATIENTS AND PERFORMANCE INDICES FOR PATIENTS WHO HAD <1% POSITIVE TUMOR CELLS FOR EGFR."|FALSE|TRUE|19|1
87|P030044||DAKOCYTOMATION EGFR PHARMDX|"immunohistochemistry assay| antibody| epidermal growth factor receptor"|2003-09-29 00:00:00|2004-02-12 00:00:00|APPROVAL FOR THE DAKOCYTOMATION EGFR PHARMDX. THE DEVICE IS INDICATED FOR: THE EGFR PHARMDX ASSAY IS A QUALITATIVE IMMUNOHISTOCHEMICAL (IHC) KIT SYSTEM TO IDENTIFY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXPRESSION IN NORMAL AND NEOPLASTIC TISSUES ROUTINELY-FIXED FOR HISTOLOGICAL EVALUATION. EGFR PHARMDX SPECIFICALLY DETECTS THE EGFR (HER1) PROTEIN IN EGFR-EXPRESSING CELLS. EGFR PHARMDX IS INDICATED AS AN AID IN IDENTIFYING COLORECTAL CANCER PATIENTS ELIGIBLE FOR TREATMENT WITH ERBITUX (CETUXIMAB).|FALSE|TRUE|19|1
88|P030044|S002|DAKO EGFR PHARMDX KIT|"immunohistochemistry assay| antibody| epidermal growth factor receptor"|2006-04-03 00:00:00|2006-09-27 00:00:00|"APPROVAL FOR ADDING A NEW THERAPY VECTIBIX (PANITUMUMAB) TO INTENDED USE. THE DEVICE| AS MODIFIED| WILL BE MARKETED UNDER THE TRADE NAME DAKO EGFR PHARMDX KIT AND IS INDICATED FOR: THE EGFR PHARMDX ASSAY IS A QUALITATIVE IMMUNOHISTOCHEMICAL (IHC) KIT SYSTEM TO IDENTIFY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXPRESSION IN NORMAL AND NEOPLATIC TISSUES ROUTINELY-FIXED FOR HISTOLOGICAL EVALUATIN. EGFR PHARMDX SPECIFICALLY DETECTS THE EGFR (HER1) PROTEIN IN EGFR-EXPRESSING CELLS. EGFR PHARMDX IS INDICATED AS AN AID IN IDENTIFYING COLORECTAL CANCER PATIENTS ELIGIBLE FOR TREATMENT WITH ERBITUX (CETUXIMAB)| OR VECTIBIX (PANITUMUMAB)."|FALSE|TRUE|19|1
89|P040011||C-KIT PHARMDX|"immunohistochemistry antibody assay| c-kit"|2004-03-12 00:00:00|2005-06-27 00:00:00|"APPROVAL FOR THE DAKOCYTOMATION C-KIT PHARMDX. DAKOCYTOMATION C-KIT PHARMDX ON THE DAKO AUTOSTAINER: THE C-KIT PHARMDX ASSAY IS A QUALITATIVE IMMUNOHISTOCHEMICAL (IHC) KIT SYSTEM USED ON THE DAKO AUTOSTAINER| FOR THE IDENTIFICATION OF C-KIT PROTEIN/CD117 ANTIGEN (C-KIT PROTEIN) EXPRESSION IN NORMAL AND NEOPLASTIC FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES FOR HISTOLOGICAL EVALUATION. THE C-KIT PHARMDX RABBIT POLYCLONAL ANTIBODIES SPECIFICALLY DETECT THE C-KIT PROTEIN IN CD117 ANTIGEN-EXPRESSING CELLS. THE C-KIT PHARMDX IS INDICATED AS AN AID IN THE DIFFERENTIAL DIAGNOSIS OF GASTROINTESTINAL STROMAL TUMORS (GIST). AFTER DIAGNOSIS OF GIST| RESULTS FROM C-KIT PHARMDX MAY BE USED AS AN AID IN IDENTIFYING THOSE PATIENTS ELIGIBLE FOR TREATMENT WITH GLEEVEC/GLIVEC (IMATINIB MESYLATE). RESULTS FROM HEMATOXYLIN AND EOSIN (H&E) STAINS AND A PANEL OF ANTIBODIES CAN AID IN THE DIFFERENTIAL DIAGNOSIS OF GIST. INTERPRETATION MUST BE MADE BY A QUALIFIED PATHOLOGIST| WITHIN THE CONTEXT OF A PATIENT'S CLINICAL HISTORY| PROPER CONTROLS| AND OTHER DIAGNOSTIC TEST. DAKO CYTOMATION C-KIT PHARMDX FOR MANUAL USE: THE C-KIT PHARMDX ASSAY IS A QUALITATIVE IMMUNOHISTOCHEMICAL (IHC) KIT SYSTEM USED FOR THE IDENTIFICATION OF C-KIT PROTEIN/CD117 ANTIGEN (C-KIT PROTEIN) EXPRESSION IN NORMAL AND NEOPLASTIC FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES FOR HISTOLOGICAL EVALUATION. THE C-KIT PHARMDX RABBIT POLYCLONAL. ANTIBODIES SPECIFICALLY DETECT THE C-KIT PROTEIN IN CD117 ANTIGEN-EXPRESSING CELLS. THE C-KIT PHARMDX IS INDICATED AS AN AID IN THE DIFFERENTIAL DIAGNOSIS OF GASTROINTESTINAL STROMAL TUMORS (GIST). AFTER DIAGNOSIS OF GIST| RESULTS FROM C-KIT PHARMDX MAY BE USED AS AN AID IN IDENTIFYING THOSE PATIENTS ELIGIBLE FOR TREATMENT WITH GLEEVEC/GLIVEC (IMATINIB MESYLATE). RESULTS FROM HEMATOXYLIN AND EOSIN (H&E) STAINS AND A PANEL OF ANTIBODIES CAN AID IN THE DIFFERENTIAL DIAGNOSIS OF GIST. INTERPRETATION MUST BE MADE BY A QUALIFIED PATHOLOGIST| WITHIN THE CONTEXT OF A PATIENT'S..."|FALSE|TRUE|21|1
90|P980024|S001|PATHVYSION HER-2 DNA PROBE KIT|"system| test| her-2/neu| nucleic acid or serum"|2001-03-30 00:00:00|2001-12-31 00:00:00|"APPROVAL FOR THE PATHVYSION HER-2 DNA PROBE KIT. THIS DEVICE IS INDICATED TO DETECT AMPLIFICATION OF THE HER-2/NEU GENE VIA FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN FORMALIN-FIXED| PARAFFIN-EMBEDDED HUMAN BREAST CANCER TISSUE SPECIMENS. RESULTS FROM THE PATHVYSION KIT ARE INTENDED FOR USE AS AN ADJUNCT TO EXISTING CLINICAL AND PATHOLOGIC INFORMATION CURRENTLY USED AS PROGNOSTIC FACTORS IN STAGE II| NODE-POSITIVE BREAST CANCER PATIENTS. THE PATHVYSION KIT IS FURTHER INDICATED AS AN AID TO PREDICT DISEASE-FREE AND OVERALL SURVIVAL IN PATIENTS WITH STAGE II| NODE POSITIVE BREAST CANCER TREATED WITH ADJUVANT CYCLOPHOSPHAMIDE| DOXORUBICIN| AND 5-FLUOROURACIL (CAF) CHEMOTHERAPY. THE PATHVYSION KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED (SEE HERCEPTIN PACKAGE INSERT)."|FALSE|TRUE|23|1
91|P980024|S011|THE PATH VYSION HER-2 DNA PRODE KIT|"system| test| her-2/neu| nucleic acid or serum"|2013-11-05 00:00:00|2013-11-27 00:00:00|"CHANGING THE CONFIGURATION OF THEIR CURRENT LABEL PRINTER| LABEL PRINTING SOFTWARE|AND LABEL INSPECTION SYSTEM FOR THE FOLLOWING FISH ASSAYS: VYSIS ALK BREAK APART FISH PROBE KIT| UROVYSION BLADDER CANCER KIT| AND PATHVYSION HER-2DNA PROBE KIT."|FALSE|TRUE|23|1
92|P980024|S022|PathVysion HER-2 DNA Probe Kit|"system| test| her-2/neu| nucleic acid or serum"|2022-02-18 00:00:00|2022-03-18 00:00:00|Extension of expiration dating of certain assay pretreatment reagent kit components.|FALSE|TRUE|23|1
93|P980024||PATHVYSION HER-2 DNA PROBE KIT|"system| test| her-2/neu| nucleic acid or serum"|1998-06-16 00:00:00|1998-12-11 00:00:00|"Approval for the PathyVysion(TM) HER-2 DNA Probe Kit. The PathyVysion(TM) HER-2 DNA Probe Kit (PathyVysion Kit) is designed to detect amplification ofthe HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded human breast cancer tissue speciments. Results from the PathVysion Kit are intended for use as an adjuncto to existing clinical and pathologic information currently used as prognostic factors in state II| node-positive breast cancer patients. The PathVysion Kit is further indicated as an aid in predct disease-free and overall survival in patients with stage II| node positive breast cancer treated with adjuvant cyclophosphamide| dosorubicin| and 5-fluorouracil (CAF) chemotherapy."|FALSE|TRUE|23|1
94|P980024|S010|PATHVYSION HER-2 DNA PROBE KIT|"system| test| her-2/neu| nucleic acid or serum"|2013-01-16 00:00:00|2013-02-10 00:00:00|ADDITION OF AN ALTERNATE SUPPLIER FOR HUMAN PLACENTAL (HP) DNA WHICH IS A COMPONENT OF THE PATHVYSION HER-2 DNA PROBE KIT AND THE UROVYSION BLADDER CANCER KIT.|FALSE|TRUE|23|1
95|P980024|S007|PATH VYSION HER-2 DNA PROBE KIT ASSAY|"system| test| her-2/neu| nucleic acid or serum"|2012-06-14 00:00:00|2012-12-20 00:00:00|"APPROVAL FOR THE MANUFACTURING CHANGE TO COMPONENTS OF THE PROBECHEK HER-2/NEU CUTOFF CONTROL SLIDES USED IN THE PATHVYSION HER-2 DNA PROBE KIT. THE CHANGE INCLUDED CREATION OF A NEW MASTER CELL BANK AND A NEW WORKING CELL BANK FROM SEED STOCK OF HS578T CELLS| USED IN THE MANUFACTURE OF THE PROBECHEK HER-2/NEU CUTOFFCONTROL SLIDES."|FALSE|TRUE|23|1
96|P980024|S014|PATH VYSION HER-2 DNA PROBE KIT|"system| test| her-2/neu| nucleic acid or serum"|2016-06-01 00:00:00|2016-07-13 00:00:00|"Removal of testing at the cell pellet stage for 2 components of the PathVysion HER-2 DNA Probe Kit: (1) ProbeChek HER-2/neu Cut-Off Control Slides (List No. 02J04-030)| (2) ProbeChek HER-2/neu Normal Control Slides (List No. 02J05-030). The second change involves adding the RM2255 Rotary Microtome to the manufacturing procedures of the ProbeChek HER-2/neu Cut-Off Control Slides| the ProbeChek Her-2/neu Normal Control Slides| and 2 components of the Vysis ALK Break Apart FISH Probe Kit: (1) ProbeChek ALK Negative Control Slides (06N38-005)| (2) ProbeChek ALK Postitive Control Slides (06N38-010)."|FALSE|TRUE|23|1
97|P980024|S006|PATHVYSION HER-2 DNA PROBE KIT|"system| test| her-2/neu| nucleic acid or serum"|2011-10-17 00:00:00|2012-02-27 00:00:00|"APPROVAL FOR MANUFACTURING PROCESS CHANGES TO THE PATHVYSION HER-2 DNA PROBE KIT| INCLUDING CHANGES ASSOCIATED WITH FISH PROBE RESTRICTION ENZYMEDIGESTED GEL ELECTROPHORESIS (DNA RESTRICTION ANALYSIS)| IMPLEMENTATION OF AN IN-PROCESS VALIDATED TEST METHOD FOR A260 ABSORBANCE READINGS| ADDITION OF AN INCOMING SCREENING TEST FOR DEXTRAN SULFATE AND REVISION TO MANUFACTURING PROCEDURE DOCUMENT FOR LSI HER-2/NEU AMINATED DNA."|FALSE|TRUE|23|1
98|P980024|S005|PATHVYSION HER-2 DNA PROBE KIT|"system| test| her-2/neu| nucleic acid or serum"|2011-02-22 00:00:00|2011-04-18 00:00:00|"APPROVAL FOR THE IMPLEMENTATION OF PROCESS CHANGES TO THE MANUFACTURE OF THE PATHVYSION HER-2 DNA PROBE KIT ASSAY| INCLUDING A NEW FISH DNA EXTRACTION PROCESS| AND RNA REDUCTION STEP| NEW SONICATION EQUIPMENT| AND A NEW AMINATION/LABELING PROCEDURE."|FALSE|TRUE|23|1
99|P980024|S016|Path Vysion HER-2 DNA Probe Kit|"system| test| her-2/neu| nucleic acid or serum"|2017-11-08 00:00:00|2017-12-06 00:00:00|Vendors relocation of a manufacturing site for production of reagents contained in kit components.|FALSE|TRUE|23|1
100|P980024|S013|PATH VYSION HER-2 DNA PROBE KIT|"system| test| her-2/neu| nucleic acid or serum"|2014-06-16 00:00:00|2014-07-16 00:00:00|"MODIFY THE VALIDATED TEST METHOD MDP00644 ¿FRAGMENTED DNA AGAROSE GEL ELECTROPHORESIS¿ OF THE MANUFACTURING PROCESS OF VYSIS ALK BREAK APART FISH PROBE KIT| PATHVYSION HER-2 DNA PROBE KIT AND UROVYSION BLADDER CANCER KIT."|FALSE|TRUE|23|1
101|P980024|S002|VYSIS PATH VYSION HER-2 DNA PROBE KIT|"system| test| her-2/neu| nucleic acid or serum"|2005-06-20 00:00:00|2006-05-10 00:00:00|"APPROVAL FOR A MANUFACTURING SITE LOCATED AT ABBOTT DES PLAINES| DES PLAINES| ILLINOIS."|FALSE|TRUE|23|1
102|P990081|S002|PATHWAY HER-2/NEU (CLONE CD11) PRIMARY ANTIBODY|"system| test| her-2/neu| ihc"|2005-09-06 00:00:00|2005-10-21 00:00:00|"APPROVAL OF LABELING CHANGES FOR THE PATHWAY HER-2/NEU (CLONE CD11) IN THE ""INTENDED USE"" SECTION| ADDITION OF AN ""OPTIONAL EQUIPMENT NOT PROVIDED"" SECTION AND CHANGES TO THE ""PRINCIPLES AND PROCEDURES"" SECTION TO REFLECT THE ADDITION OF TRIPATH IMAGING VIAS INSTRUMENT TO BE USED IN CONJUNCTION WITH THE VENTANA PATHWAY HER 2 ASSAY AS AN OPTIONAL ACCESSORY. THE DEVICE| AS MODIFIED| WILL BE MARKETED UNDER THE SAME TRADE NAME PATYHWAY HER-2/NEU (CLONE CD11) AND IS INDICATED: VENTANA MEDICAL SYSTEMS| INC.'S (VENTANA) PATHWAY HER 2 (CLONE CD11) IS A MOUSE MONOCLONAL ANTIBODY INTENDED FOR LABORATORY USE FOR THE SEMI-QUANTITATIVE DETECTION OF C-ERBB2- ANTIGEN IN SECTIONS OF FORMALIN FIXED| PARAFFIN EMBEDDED NORMAL AND NEOPLASTIC TISSUE ON A VENTANA AUTOMATED IMMUNOHISTOCHEM-ISTRY SLIDE STAINING DEVICE. IT IS INDICATED AS AN AID IN THE ASSESSMENT OF BREAST CANCER PATIENTS FOR WHOM HERCEPTIN TREATMENT IS CONSIDERED. NOTE: ALL OF THE PATIENTS IN THE HERCEPTIN CLINICAL TRIALS WERE SELECTED USING A CLINICAL TRIAL ASSAY. NONE OF THE PATIENTS IN THOSE TRIALS WERE SELECTED USING PATHWAY HER 2. THE PATHWAY HER 2 WAS COMPARED TO THE DAKO HERCEPTEST ON AN INDEPENDENT SAMPLE AND FOUND TO PROVIDE ACCEPTABLY CONCORDANT RESULTS. THE ACTUAL CORRELATION OF PATHWAY HER 2 TO CLINICAL OUTCOME HAS NOT BEEN ESTABLISHED. THE VENTANA IMAGE ANALYSIS SYSTEM (VIAS) IS ADJUNCTIVE OPTIONAL COMPUTER-ASSISTED IMAGE ANALYSIS SYSTEM FUNCTIONALLY CONNECTED TO AN INTERACTIVE MICROSCOPE. IT IS INTENDED FOR USE AS AN AID TO THE PATHOLOGIST IN THE DETECTION CLASSIFICATION AND COUNTING OF CELLS OF INTEREST BASED ON MARKET INTENSITY| SIZE AND SHAPE USING APPROPRIATE CONTROLS TO ASSURE THE VALIDITY OF THE VIAS SCORES."|FALSE|TRUE|24|1
103|P990081|S012|PATWAY HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|"system| test| her-2/neu| ihc"|2012-07-25 00:00:00|2012-08-21 00:00:00|APPROVAL FOR AN EXTENSION OF SHELF LIFE OF THE IVIEW DAB DETECTIONKIT AND THE ULTRAVIEW DAB DETECTION KIT FOR THE PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY.|FALSE|TRUE|24|1
104|P990081|S022|PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|"system| test| her-2/neu| ihc"|2013-08-30 00:00:00|2013-10-02 00:00:00|"ADD A SUPPLIER (ROCHE| PENZBERG) OF A COMPONENT (STREPTAVIDIN HORSERADISH PEROXIDASE) FOR THE IVIEW DAB DETECTION KIT."|FALSE|TRUE|24|1
105|P990081|S013|PATHWAY HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|"system| test| her-2/neu| ihc"|2012-07-27 00:00:00|2012-08-09 00:00:00|"ADDITION OF A SUPPLIER OF RAW MATERIALS FOR THE IVIEW DETECTION KIT| WHICH IS PARTOF THE DEVICE."|FALSE|TRUE|24|1
106|P990081|S020|PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|"system| test| her-2/neu| ihc"|2013-05-07 00:00:00|2013-10-25 00:00:00|APPROVAL FOR ADDITION OF A NEW SUPPLIER OF BIOCONJUGATES FOR THE ULTRAVIEW UNIVERSAL DAB DETECTION KIT. THE DETECTION KIT IS PART OF THE PATHWAY ANTI-HER 2/NEU RABBIT MONOCLONAL PRIMARY ANTIBODY (4B5).|FALSE|TRUE|24|1
107|P990081|S003|PATHWAY ANTI-HER-2/NEU (4B5) PRIMARY ANTIBODY|"system| test| her-2/neu| ihc"|2006-05-04 00:00:00|2007-01-11 00:00:00|"APPROVAL FOR MODIFICATIONS TO THE PATHWAY C-ERBB-2 PRIMARY ANTIBODY(CLONE CB11) WHICH INCLUDE 1) CHANGE THE PRIMARY ANTIBODY FROM THE MOUSE MONOCLONAL ANTIBODY CB11 TO THE RABBIT MONOCLONAL ANTIBODY 4B5| 2) CHANGE THE DETECTION FORMAT FROM BASIC DAB DETECTION KIT TO THE VENTANA MEDICAL SYSTEMS IVIEW DAB DETECTION KIT| 3) ADD THE OPTIONAL ULTRAVIEW UNIVERSAL DAB DETECTION KIT FOR BIOTIN FREE DETECTION FORMAT| 4) CONSOLIDATE LEVEL 1|3 AND NEGATIVE HER-2 ASSAY CONTROL SLIDES ONTO A SINGLE SLIDE AND ADD A LEVEL 2 ASSAY CONTROL AND THE CONTROL WILL BE MARKETED UNDER THE TRADE NAME OF PATHWAY HER2 4 IN 1 CONTROL SLIDE| AND 5) INCLUDE THE VENTANA IMAGE ANALYSIS SYSTEM (VIAS) IN THE LABELING. THE DEVICE| AS MODIFIED| WILL BE MARKETED UNDER THE TRADE NAME PATHWAY ANTI-HER-2/NEU (4B5) PRIMARY ANTIBODY AND IS INDICATED FOR: VENTANA MEDICAL SYSTEMS| INC.?S (VENTANA) PATHWAY ANTI-HER-2/NEU (4B5) PRIMARY ANTIBODY (PATHWAY HER2 (4B5)) IS A RABBIT MONOCLONAL ANTIBODY INTENDED FOR LABORATORY USE FOR THE SEMI-QUANTITATIVE DETECTION OF HER2 ANTIGEN IN SECTIONS OF FORMALIN-FIXED| PARAFFIN-EMBEDDED NORMAL AND NEOPLASTIC TISSUE ON A VENTANA AUTOMATED IMMUNOHISTOCHEMISTRY SLIDE STAINING DEVICE. IT IS INDICATED AS AN AID IN THE ASSESSMENT OF BREAST CANCER PATIENTS FOR WHOM HERCEPTIN TREATMENT IS BEING CONSIDERED."|FALSE|TRUE|24|1
108|P990081|S039|PATHWAY Anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody|"system| test| her-2/neu| ihc"|2019-02-13 00:00:00|2019-05-03 00:00:00|"Approval for the Ventana Medical Systems| Inc.'s (Ventana) PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (PATHWAY HER2 (4B5)) is a rabbit monoclonal antibody intended for laboratory use for the semi-quantitative detection of HER2 antigen in sections of formalin-fixed| paraffin-embedded normal and neoplastic tissue following staining on a BenchMark XT or BenchMark ULTRA instrument. It is indicated as an aid in the assessment of breast cancer patients for whom Herceptin (trastuzumab) or KADCYLA (ado-trastuzumab emtansine) treatment is being considered.Note: All of the patients in the Herceptin clinical trials were selected using a clinical trial assay. None of the patients in those trials were selected using PATHWAY anti-HER-2/neu (4B5). PATHWAY anti-HER-2/neu (4B5) was compared to PATHWAY HER-2 (clone CB11) Primary Antibody on an independent sample set and found to provide acceptably concordant results. The actual correlation of PATHWAY anti-HER-2/neu (4B5) to clinical outcome has not been established.This product should be interpreted by a qualified pathologist in conjunction with histological examination| relevant clinical information| and proper controls.This antibody is intended for in vitro diagnostic (IVD) use."|FALSE|TRUE|24|1
109|P040030||INSITE HER-2/NEU KIT|"system| test| her-2/neu| ihc"|2004-06-22 00:00:00|2004-12-22 00:00:00|"APPROVAL FOR THE INSITE HER-2/NEU KIT. THE DEVICE IS INDICATED FOR: INSITE HER-2/NEU MOUSE MONOCLONAL ANTIBODY (CLONE CB11) KIT IS INTENDED FOR IN VITRO DIAGNOSTIC USE IN IMMUNOHISTOCHEM-ISTRY (IHC) ASSAYS TO SEMI-QUANTITATIVELY LOCALIZED BY LIGHT MICROSCOPY THE OVER-EXPRESSION OF HER-2/NEU (I.E.| C-ERBB-2) IN FORMALIN-FIXED| PARAFFIN-EMBEDDED NORMAL AND NEOPLASTIC TISSUE SECTIONS. INSITE HER-2/NEU IS INDICATED AS AN AID IN THE ASSESSMENT OF BREAST CANCER PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) THERAPY IS BEING CONSIDERED. CLINICAL INTERPRETATION OF INSITE HER-2/NEU IMMUNOSTAINING RESULTS (ABSENCE OR PRESENCE; SEMI-QUANTITATIVE INTENSITY SCORE) SHOULD BE COMPLEMENTED BY APPROPRIATE CONTROLS AND MORPHOLOGICAL TISSUE ANALYSIS AND BE EVALUATED BY A QUALIFIED PATHOLOGIST WITHIN THE CONTEXT OF PATIENT CLINICAL HISTORY AND OTHER DIAGNOSTIC RESULTS."|FALSE|TRUE|25|1
110|P050040||SPOT-LIGHT HER2 CISH KIT|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2005-11-03 00:00:00|2008-07-01 00:00:00|"APPROVAL FOR SPOT-LIGHT HER2 CISH KIT. THIS DEVICE IS INDICATED FOR: THE SPOT-LIGHT HER2 CISH KIT IS INTENDED TO QUANTITATIVELY DETERMINE HER2 GENE AMPLIFICATION IN FORMALIN-FIXED| PARAFFIN-EMBEDDED (FFPE) BREAST CARCINOMA TISSUE SECTIONS USING CHROMOGENIC IN SITU HYBRIDIZATION (CISH) AND BRIGHTFIELD MICROSCOPY. THIS TEST SHOULD BE PERFORMED IN A HISTOPATHOLOGY LABORATORY. THE SPOT-LIGHT HER2 CISH KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED. THE ASSAY RESULTS ARE INTENDED FOR USE AS AN ADJUNCT TO THE CLINICOPATHOLOGICAL INFORMATION CURRENTLY BEING USED AS PART OF THE MANAGEMENT OF BREAST CANCER PATIENTS. INTERPRETATION OF TEST RESULTS MUST BE MADE WITHIN THE CONTEXT OF THE PATIENT'S CLINICAL HISTORY BY A QUALIFIED PATHOLOGIST."|FALSE|TRUE|26|1
111|P100024|S008|HER2 CISH PHARMDX KIT|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2016-01-08 00:00:00|2016-01-29 00:00:00|"CHANGE OF THE IN-PROCESS QC ""METAPHASE FISH TEST'| WITH CHANGE NUMBER R02285. PMA APPROVED DEVICES AFFECTED BY THE CHANGE ARE: HER2 CISH PHARMDX KIT AND HER2 IQFISH PHARMDX."|FALSE|TRUE|28|1
112|P100024||HER2 CISH PHARMDX KIT|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2010-06-21 00:00:00|2011-11-30 00:00:00|"APPROVAL FOR THE HER2 CISH PHARMDX KIT. THIS DEVICE IS INDICATED TOR;HER2 CISH PHARMDX KIT IS INTENDED FOR DUAL-COLOR CHROMOGENIC VISUALIZATION OF SIGNALS ACHIEVED WITH DIRECTLY LABELED IN SITU HYBRIDIZATION PROBES TARGETING THE HER2 GENE AND CENTROMERIC REGION OF CHROMOSOME 17. THE KIT IS DESIGNED TO QUANTITATIVELY DETERMINE HER2 GENE STATUS IN FORMALIN-FIXED| PARAFFIN-EMBEDDED BREAST CANCER TISSUE SPECIMENS. RED AND BLUE CHROMOGENIC SIGNALS ARE GENERATED ON THE SAME TISSUE SECTION FOR EVALUATION UNDER BRIGHT FIELD MICROSCOPY. THE CISH PROCEDURE IS AUTOMATED USING DAKO AUTOSLAINERINSTRUMENTS. HER2 CISH PHARMDX KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED. RESULTS FROM THE HER2 CISH PHARMDX KIT ARE INTENDED FOR USE AS AN ADJUNCT TO THE CLINICOPATHOLOGIC INFORMATIONCURRENTLY USED FOR ESTIMATING PROGNOSIS IN STAGE II| NODE-POSITIVE BREAST CANCER PATIENTS."|FALSE|TRUE|28|1
113|P100024|S003|HER2 CISH PHARMDX KIT|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2012-09-20 00:00:00|2012-11-27 00:00:00|APPROVAL FOR A CHANGE IN THE MOUNTING MEDIUM REAGENT SUPPLIED IN THE KIT.|FALSE|TRUE|28|1
114|P100024|S004|HER2 CISH PHARMDX KIT|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2012-11-16 00:00:00|2013-04-19 00:00:00|APPROVAL FOR THE DAKOLINK V4.0 SOFTWARE FOR HER2 CISH PHARMDX¿ KIT.|FALSE|TRUE|28|1
115|P100024|S010|HER2 CISH PHARMDX KIT|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2016-07-01 00:00:00|2016-09-27 00:00:00|Approval for the DakoLink software version 4.1 update for the HER2 CISH pharmDx Kit|FALSE|TRUE|28|1
116|P100027|S010|INFORM HER-2 DUAL ISH DNA PROBE COCKTAIL|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2013-05-07 00:00:00|2013-05-29 00:00:00|"QUALIFICATION OF A NEW SUPPLIER FOR A RAW MATERIAL THAT IS USED IN THE MANUFACTURE OF THE DETECTION KIT ASSOCIATED WITH THE INFORM HER-2 DUAL ISH DNA PROBE COCKTAIL. AS PART OF THIS CHANGE IN RAW MATERIAL| A CHANGE IN THE CELL MEDIA USED TO GROW THE ANTI-DNP ANTIBODY IS ALSO BEING IMPLEMENTED."|FALSE|TRUE|29|1
117|P100027|S011|INFORM HER-2 DUAL ISH DNA PROBE COCKTAIL|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2013-09-12 00:00:00|2013-10-10 00:00:00|ADDITION OF A NEW SUPPLIER OF TWO BIOCONJUGATES FOR THE ULTRAVIEW SISH DNP DETECTION KIT AND THE ULTRAVIEW RED ISH DIG DETECTION KIT. BOTH DETECTION KITS ARE PARTS OF THE INFORM HER2 DUAL ISH DNA PROBE COCKTAIL.|FALSE|TRUE|29|1
118|P100027|S018|INFORM HER2 DUAL ISH DNA PROBE COCKTAIL|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2014-05-01 00:00:00|2014-07-30 00:00:00|"APPROVAL FOR THE EXTENSION OF STABILITY DATING FOR THE INFORM HER2 DUAL ISH DNA PROBE COCKTAIL SYSTEM| WHICH INCLUDES THE FOLLOWING PRODUCTS: INFORM HER2 DUAL ISH DNA PROBE COCKTAIL| ULTRAVIEW RED ISH DIG DETECTION KIT| ULTRAVIEW SISH DNP DETECTION KIT."|FALSE|TRUE|29|1
119|P100027|S005|INFORM HER-2 DUAL ISH DNA PROBE COCKTAIL|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2012-10-10 00:00:00|2013-03-26 00:00:00|"APPROVAL FOR HARDWARE MODIFICATION AND SOFTWARE UPGRADES TO THE BENCHMARK| ULTRA INSTRUMENT. THE PURPOSE OFTHESE DESIGN CHANGES WAS TO IMPLEMENT ULTIMATE REAGENT ACCESS (URA) FEATURE ON THE BENCHMARK ULTRA INSTRUMENT."|FALSE|TRUE|29|1
120|P100027|S030|INFORM HER2 Dual ISH DNA Probe Cocktail assays|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2019-02-13 00:00:00|2019-05-03 00:00:00|"Approval for the Ventana Medical Systems| Inc’s (Ventana) INFORM HER2 Dual ISH DNA Probe Cocktail is intended to determine HER2 gene status by enumeration of the ratio of the HER2 gene to Chromosome 17. The HER2 and Chromosome 17 probes are detected by light microscopy using two color chromogenic in situ hybridization (ISH) in formalin-fixed| paraffin-embedded human breast cancer tissue specimens following staining on a BenchMark XT or BenchMark ULTRA instrument. The INFORM HER2 Dual ISH DNA Probe Cocktail is indicated as an aid in the assessment of breast cancer patients for whom Herceptin (trastuzumab) or KADCYLA (ado-trastuzumab emtansine) treatment is being considered. This product should be interpreted by a qualified reader in conjunction with histological examination| relevant clinical information| and proper controls.This reagent is intended for in vitro diagnostic (IVD) use."|FALSE|TRUE|29|1
121|P100027|S002|INFORM HER2 DUAL ISH DNA PROBE COCKTAIL|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2011-09-19 00:00:00|2012-02-15 00:00:00|"APPROVAL FOR MIGRATION OF THE INFORM HER2 DUAL ISH DNA PROBE COCKTAIL ASSAY TO THE BENCHMARK ULTRA AUTO-STAINER. THE DEVICE| AS MODIFIED| WILL BE MARKETED UNDER THE TRADE NAME INFORM HER2 DUAL ISH DNA PROBE COCKTAIL ASSAY AND IS INDICATED FOR USE INDETERMINING HER2 GENE STATUS BY ENUMERATION OF THE RATIO OF THE HER2 GENE TO CHROMOSOME 17. THE HER2 AND CHROMOSOME 17 PROBES ARE DETECTED USING TWO COLOR CHROMOGENIC IN SITU HYBRIDIZATION (ISH) IN FORMALIN-FIXED| PARAFFIN-EMBEDDED HUMAN BREAST CANCER TISSUE SPECIMENS FOLLOWING STAINING ON VENTANA BENCHMARK XT AUTOMATED SLIDE STAINERS (USING NEXES SOFTWARE)| OR ON VENTANA BENCHMARK ULTRA AUTOMATED SLIDE STAINER (USING VSS SOFTWARE)| BY LIGHTMICROSCOPY. THE INFORM HER2 DUAL ISH DNA PROBE COCKTAIL IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED.THIS PRODUCT SHOULD BE INTERPRETED BY A QUALIFIED READER IN CONJUNCTION WITH HISTOLOGICAL EXAMINATION| RELEVANT CLINICAL INFORMATION| AND PROPER CONTROLS. THIS REAGENT IS INTENDED FOR IN VITRO DIAGNOSTIC (IVD) USE."|FALSE|TRUE|29|1
122|P100027||INFORM HER2 DUAL ISH DNA PROBE COCKTAIL|"chromogenic in situ hybridization| nucleic acid amplification| her2/neu gene| breast cancer"|2010-07-12 00:00:00|2011-06-14 00:00:00|"APPROVAL FOR THE INFORM HER2 DUAL ISH DNA PROBE COCKTAIL. THIS DEVICE IS INDICATED FOR:THE INFORM HER2 DUAL ISH DNA PROBE COCKTAIL IS INTENDED FOR USE IN DETERMINING HER2 GENE STATUS BY ENUMERATION OF THE RATIO OF THE HER2 GENE TO CHROMOSOME 17. THE HER2 AND CHROMOSOME 17 PROBES ARE DETECTED USING TWO COLOR CHROMOGENIC IN SITU HYBRIDIZATION (ISH) IN FORMALIN-FIXED. PARAFFIN-EMBEDDED HUMAN BREAST CANCER TISSUE SPECIMENS FOLLOWING STAINING ON VENTANA BENCHMARK XT AUTOMATED SLIDE STAINERS (USING NEXES SOFTWARE)| BY LIGHT MICROSCOPY. THE INFORM HER2 DUAL ISH DNA PROBE COCKTAIL IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM I-HERPCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED.THIS PRODUCT SHOULD BE INTERPRETED BY A QUALIFIED READER IN CONJUNCTION WITH HISTOLOGICAL EXAMINATION| RELEVANT CLINICAL INFORMATION| AND PROPER CONTROLS.THIS REAGENT IS INTENDED FOR IN VITRO DIAGNOSTIC (IVD) USE."|FALSE|TRUE|29|1
123|P980018|S007|HERCEPTEST|"system| test| her-2/neu| ihc"|2009-12-31 00:00:00|2010-01-21 00:00:00|CHANGES IN THE CONTROL SLIDES FOR THE HERCEPTEST¿ KIT.|FALSE|TRUE|30|1
124|P980018|S010|HERCEPTEST|"system| test| her-2/neu| ihc"|2010-04-21 00:00:00|2010-10-20 00:00:00|"APPROVAL FOR THE HERCEPTEST KIT. THE DEVICE IS INDICATED FOR IN VITRO DIAGNOSTIC USE. HERCEPTEST IS A SEMI-QUANTITATIVE IMMUNOCYTOCHEMI-CAL ASSAY TO DETERMINE HER2 PROTEIN OVEREXPRESSION IN BREAST CANCER TISSUES ROUTINELY PROCESSED FOR HISTOLOGICAL EVALUATION AND FORMALIN-FIXED| PARAFFIN-EMBEDDED CANCER TISSUE FROM PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA. HERCEPTEST IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED (SEE HERCEPTIN PACKAGE INSERT)."|FALSE|TRUE|30|1
125|P980018|S011|HERCEPTEST KIT|"system| test| her-2/neu| ihc"|2010-09-09 00:00:00|2011-02-17 00:00:00|APPROVAL OF THE DAKOLINK V3.1.0. SOFTWARE FOR HERCEPTEST KIT.|FALSE|TRUE|30|1
126|P980018|S017|HERCEPTEST|"system| test| her-2/neu| ihc"|2012-11-01 00:00:00|2013-04-18 00:00:00|APPROVAL FOR THE DAKOLINK. V4.0 SOFTWARE FOR HERCEPTEST¿ KIT.|FALSE|TRUE|30|1
127|P980018|S006|HERCEP TEST|"system| test| her-2/neu| ihc"|2008-05-28 00:00:00|2010-02-25 00:00:00|"APPROVAL TO MARKET THE HERCEPTEST KIT FOR AUTOMATED LINK PLATFORMS AND THE CHANGES INVOLVED IN THE ASSAY PROCEDURE TO USE THE NEW INSTRUMENT| CHANGE IN THE QC PROCEDURE WITH REFERENCE TO CHROMOGEN| CHANGES IN THE CRITERIA REGARDING THE CONTROL TISSUE DURING QC AND CHANGES IN THE SPECIMEN PREPARATION."|FALSE|TRUE|30|1
128|P040005|S012|HER2 IQFISH PHARMDX|"system| test| her-2/neu| nucleic acid or serum"|2016-01-08 00:00:00|2016-01-29 00:00:00|"CHANGE OF THE IN-PROCESS QC ""METAPHASE FISH TEST'| WITH CHANGE NUMBER R02285. PMA APPROVED DEVICES AFFECTED BY THE CHANGE ARE: HER2 CISH PHARMDX KIT AND HER2 IQFISH PHARMDX."|FALSE|TRUE|31|1
129|P040005||DAKOCYTOMATION HER2 FISH PHARMDX KIT|"system| test| her-2/neu| nucleic acid or serum"|2004-01-29 00:00:00|2005-05-03 00:00:00|"APPROVAL FOR THE DAKOCYTOMATION HER2 FISH PHARMDX KIT. THE DEVICE IS INDICATED FOR: THE DAKOCYTOMATION HER2 FISH PHARMDX KIT IS A DIRECT FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ASSAY DESIGNED TO QUANTITATIVELY DETERMINE THE HER2 GENE AMPLIFICATION IN FORMALIN-FIXED| PARAFFIN-EMBEDDED BREAST CANCER TISSUE SPECIMENS. HER2 FISH PHARMDX KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED. RESULTS FORM THE HER2 FISH PHARMDX KIT ARE INTENDED FOR USE AS AN ADJUNCT TO THE CLINICOPATHOLOGIC INFORMATION CURRENTLY USED FOR ESTIMATING PROGNOSIS IN STAGE II| NODE POSITIVE BREAST CANCER PATIENTS."|FALSE|TRUE|31|1
130|P040005|S006|HER2 FISH PHARMADX KIT|"system| test| her-2/neu| nucleic acid or serum"|2011-12-05 00:00:00|2012-06-08 00:00:00|"APPROVAL FOR ADDITION OF PERTUZUMAB IN THE LABELING OF HER2 FISH PHARMDX KIT. THE DEVICE| AS MODIFIED| WILL BE MARKETED UNDER THE TRADE NAME HER2 FISH PHARMDX KIT AND ITS INDICATION FOR USE IS: A DIRECT FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ASSAY DESIGNED TOQUANTITATIVELY DETERMINE HER2 GENE AMPLIFICATION IN FORMALIN-FIXED| PARAFFIN-EMBEDDED (FFPE) BREAST CANCER TISSUE SPECIMENS AND FFPE SPECIMENS FROM PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA. HER2 FISH PHARMDX KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF BREAST AND GASTRIC CANCER PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED AND FOR BREAST CANCER PATIENTS FOR WHOM PERJETA (PERTUZUMAB) TREATMENT IS BEING CONSIDERED (SEE HERCEPTIN AND PERJETA PACKAGE INSERTS)."|FALSE|TRUE|31|1
131|P040005|S009|HER2 FISH PHARMADX KIT|"system| test| her-2/neu| nucleic acid or serum"|2012-08-24 00:00:00|2013-02-22 00:00:00|APPROVAL FOR ADDITION OF KADCYLA (ADO-TRASTUZUMAB EMTANSINE) IN THE LABELING OF HER2 IQ-FISH PHARMDX KIT.|FALSE|TRUE|31|1
132|P040005|S005|HER2 FISH PHARMDX KIT|"system| test| her-2/neu| nucleic acid or serum"|2010-04-20 00:00:00|2010-10-20 00:00:00|"APPROVAL FOR THE HER2 FISH PHARMDX KIT. THE DEVICE IS INDICATED FOR IN VITRO DIAGNOSTIC USE. THE HER2 FISH PHARMDX KIT IS A DIRECT FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ASSAY DESIGNED TO QUANTITATIVELY DETERMINE HER2 GENE AMPLIFICATION IN FORMALIN-FIXED| PARAFFIN-EMBEDDED (FFPE) BREAST CANCER TISSUE SPECIMENS AND FFPE SPECIMENS FROM PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA. HER2 FISH PHARMDX KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED (SEE HERCEPTIN PACKAGE INSERT)."|FALSE|TRUE|31|1
133|P040005|S007|HER2 IQFISH PHARMDX|"system| test| her-2/neu| nucleic acid or serum"|2011-12-14 00:00:00|2012-12-05 00:00:00|"APPROVAL FOR MODIFICATIONS TO THE FORMULATION OF THE HER2 FISH PHARMDX KIT. THE DEVICE| AS MODIFIED| WILL BE MARKETED UNDER THE TRADE NAME HER2 IQFISH PHARMDX."|FALSE|TRUE|31|1
134|P120014||BIOMERIEUX THXID BRAF ASSAY KIT|somatic gene mutation detection system|2012-07-31 00:00:00|2013-05-29 00:00:00|APPROVAL FOR THE THXID BRAF KIT FOR USE ON THE ABI 7500 FAST DX REAL-TIME PCR INSTRUMENT. THIS DEVICE IS INDICATED FOR: THE THXID BRAF KIT IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION OF THE BRAF V600E AND V600K MUTATIONS IN DNA SAMPLES EXTRACTED FROM FORMALIN-FIXED PARAFFINEMBEDDED (FFPE) HUMAN MELANOMA TISSUE. THE THXID BRAF KIT IS A REAL-TIME PCR TEST ON THE ABI 7500 FAST DX SYSTEM AND IS INTENDED TO BE USED AS AN AID IN SELECTING MELANOMA PATIENTS WHOSE TUMORS CARRY THE BRAF V600E MUTATION FOR TREATMENT WITH DABRAFENIB [TAFINLAR] AND AS AN AID IN SELECTING MELANOMA PATIENTS WHOSE TUMORS CARRY THE BRAF V600E OR V600K MUTATION FOR TREATMENT WITH TRAMETINIB [MEKINIST].|FALSE|TRUE|32|1
135|P120014|S008|THxID BRAF assay kit|somatic gene mutation detection system|2017-07-03 00:00:00|2018-06-27 00:00:00|"Approval for the THxID-BRAF kit. It is an In Vitro Diagnostic device intended for the qualitative detection of the BRAF V600E and V600K mutations in DNA samples extracted from formalin-fixed paraffin-embedded (FFPE) human melanoma tissue. The THxID-BRAF kit is a real-time PCR test on the ABI 7500 Fast Dx system and is intended to be used as an aid in selecting melanoma patients whose tumors carry: the BRAF V600E or V600K mutation for treatment with encorafenib [Braftovi] in combination with binimetinib [Mektovi]| the BRAF V600E mutation for treatment with dabrafenib [Tafinlar]| the BRAF V600E or V600K mutation for treatment with trametinib [Mekinist]."|FALSE|TRUE|32|1
136|P120014|S006|THXID-BRAF KIT|somatic gene mutation detection system|2016-01-11 00:00:00|2016-04-05 00:00:00|Approval for a change in the THxID-BRAF software to detect a specific fallback threshold value within the SDS file and in such case prevent the generation of a mutation report.|FALSE|TRUE|32|1
137|P120014|S005|THXID BRAF KIT|somatic gene mutation detection system|2015-05-08 00:00:00|2015-06-05 00:00:00|CHANGE IN THE METHOD USED TO DETERMINE THE CONCENTRATION OF THE OLIGONUCLEOTIDES AND PROBES USED IN THE TEST KIT.|FALSE|TRUE|32|1
138|P120014|S002|THXID BRAF KIT|somatic gene mutation detection system|2014-10-15 00:00:00|2014-12-22 00:00:00|"APPROVAL FOR THE FOLLOWING SEVEN CHANGES: CLEANING OF DRIPPING AND SPHERES FILLING EQUIPMENT| TRANSFER OF QUALITY CONTROL ACTIVITIES INTO ANOTHER ROOM| RAW MATERIAL CHANGES FOR BOTTLES AND CAPS FOR THXID-BRAF PUR| MODIFICATION OF A FUNCTIONAL QUALITY CONTROL (QC) TEST FOR THE THXIDTM-BRAF PUR KIT| TRANSFER OF BUFFER MANUFACTURING (FOR THE BRAF PURIFICATION KIT) INTO A NEW BUILDING AT QIAGEN| CHANGES IN DNASE REFERENCE (AM2224) USED IN THE DETERMINATION OF DNASE ACTIVITY IN WATER AND REAGENTS| AND SHELF LIFE EXTENSION FOR RNA TRANSCRIPTS AND PLASMIDS."|FALSE|TRUE|32|1
139|P120014|S003|THXID BRAF KIT|somatic gene mutation detection system|2015-02-24 00:00:00|2015-05-27 00:00:00|APPROVAL FOR USING THE UPDATED ABI 7500 FAST DX OPERATING SYSTEM AND SDS SOFTWARE.|FALSE|TRUE|32|1
140|P110012||"VYSIS ALK BREAK APART FISH PROBE KIT| VYSIS PARAFFIN PRETREATMENT IV & POST HYBRIDIZATION WASH BUFFER KIT PROBECHEK ALK"|"fluorescence in situ hybridization| anaplastic lymphoma kinase| gene rearrangement"|2011-04-01 00:00:00|2011-08-26 00:00:00|APPROVAL FOR THE VYSIS ALK BREAK APART FISH PROBE KIT; VYSIS PARAFFIN PRETREATMENT IV & POST HYBRIDIZATION WASH BUFFER KIT; PROBECHEK ALK NEGATIVE CONTROL SLIDES; AND PROBECHEK ALK POSITIVE CONTROL SLIDES. THIS DEVICE IS INDICATED FOR: THE VYSIS ALK BREAK APART FISH PROBE KIT IS A QUALITATIVE TEST TO DETECT REARRANGEMENTS INVOLVING THE ALK GENE VIA FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN FORMALIN-FIXED PARAFFIN -EMBEDDED (FFPE) NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE SPECIMENS TO AID IN IDENTIFYING THOSE PATIENTS ELIGIBLE FOR TREATMENT WITH XALKORI CRIZOTINIB). THE TEST IS FOR PRESCRIPTION USE ONLY. THE VYSIS PARAFFIN PRETREATMENT IV & POST HYBRIDIZATION WASH BUFFER KIT IS USED TO PREPARE PARAFFIN-EMBEDDED LUNG CANCER TISSUE SECTIONS FIXED ON POSITIVELY CHARGED SLIDES FOR USE IN FLUORESCENCE IN SITU HYBRIDIZATION (FISH) WITH VYSIS DNA FISH PROBES.THE PROBECHEK ALK NEGATIVE CONTROL SLIDES ARE INTENDED FOR USE AS AN ASSAY CONTROL FOR APPROPRIATE HYBRIDIZATION CONDITIONS DURING ROUTINE USE OF THE VYSIS ALK BREAK APART FISH PROBE KIT (LIST NO. 06N38-020). THE PROBECHEK ALK NEGATIVE CONTROL SLIDES SHOULD BE ASSAYED IN CONJUNCTION WITH THE USER'S SPECIMEN SLIDES ACCORDING THE PACKAGE INSERT FOR THE VYSIS ALK BREAK APART FISH PROBE KIT (LIST NO. 06N38-020). THE PROBECHEK ALK POSITIVE CONTROL SLIDES ARE INTENDED FOR USE AS AN ASSAY CONTROL FOR APPROPRIATE HYBRIDIZATION CONDITIONS DURING ROUTINE USE OF THE VYSIS ALK BREAK APART FISH PROBE KIT (LIST NO. 06N38-020). THE PROBECHEK ALK POSITIVE CONTROL SLIDES SHOULD BE ASSAYED IN CONJUNCTION WITH THE USER'S SPECIMEN SLIDES ACCORDING THE PACKAGE INSERT FOR THE VYSIS ALK BREAK APART FISH PROBE KIT (LIST NO. 06N38-020).|FALSE|TRUE|33|1
141|P110012|S001|VYSIS ALK BREAK APART FISH PROBE KIT|"fluorescence in situ hybridization| anaplastic lymphoma kinase| gene rearrangement"|2011-12-19 00:00:00|2012-06-07 00:00:00|"APPROVAL FOR ADDITION OF AN ALTERNATE SUPPLIER FOR THE HUMAN PLACENTAL (HP) DNA COMPONENT FOR THE DEVICE| PER DESIGN VERIFICATION PROTOCOL MD17892."|FALSE|TRUE|33|1
142|P110012|S005|VYSIS ALK BREAK APART FISH PROBE KIT|"fluorescence in situ hybridization| anaplastic lymphoma kinase| gene rearrangement"|2013-11-05 00:00:00|2013-11-27 00:00:00|"CHANGING THE CONFIGURATION OF THEIR CURRENT LABEL PRINTER| LABEL PRINTING SOFTWARE|AND LABEL INSPECTION SYSTEM FOR THE FOLLOWING FISH ASSAYS: VYSIS ALK BREAK APART FISH PROBE KIT| UROVYSION BLADDER CANCER KIT| AND PATHVYSION HER-2DNA PROBE KIT."|FALSE|TRUE|33|1
143|P110012|S010|VYSIS ALK BREAK APART FISH PROBE KIT|"fluorescence in situ hybridization| anaplastic lymphoma kinase| gene rearrangement"|2016-06-01 00:00:00|2016-07-13 00:00:00|"Removal of testing at the cell pellet stage for 2 components of the PathVysion HER-2 DNA Probe Kit: (1) ProbeChek HER-2/neu Cut-Off Control Slides (List No. 02J04-030)| (2) ProbeChek HER-2/neu Normal Control Slides (List No. 02J05-030). The second change involves adding the RM2255 Rotary Microtome to the manufacturing procedures of the ProbeChek HER-2/neu Cut-Off Control Slides| the ProbeChek Her-2/neu Normal Control Slides| and 2 components of the Vysis ALK Break Apart FISH Probe Kit: (1) ProbeChek ALK Negative Control Slides (06N38-005)| (2) ProbeChek ALK Postitive Control Slides (06N38-010)."|FALSE|TRUE|33|1
144|P110012|S006|VYSIS ALK BREAK APART FISH PROBE KIT|"fluorescence in situ hybridization| anaplastic lymphoma kinase| gene rearrangement"|2014-06-16 00:00:00|2014-07-16 00:00:00|"MODIFY THE VALIDATED TEST METHOD MDP00644 FRAGMENTED DNA AGAROSE GEL ELECTROPHORESIS OF THE MANUFACTURING PROCESS OF VYSIS ALK BREAK APART FISH PROBE KIT| PATHVYSION HER-2 DNA PROBE KIT AND UROVYSION BLADDER CANCER KIT."|FALSE|TRUE|33|1
145|P110012|S014|Vysis ALK Break Apart Fish Probe Kit|"fluorescence in situ hybridization| anaplastic lymphoma kinase| gene rearrangement"|2017-11-08 00:00:00|2017-12-06 00:00:00|Vendors relocation of a manufacturing site for production of reagents contained in kit components.|FALSE|TRUE|33|1
146|P110012|S020|Vysis ALK Break Apart Fish Probe Kit|"fluorescence in situ hybridization| anaplastic lymphoma kinase| gene rearrangement"|2019-12-23 00:00:00|2020-05-22 00:00:00|"Approval of the expansion of the Indications for Use for the Vysis ALK Break Apart FISH Probe Kit to include an indication for ALUNBRIG (brigatinib). The device| as modified| will be marketed under the trade name Vysis ALK Break Apart FISH Probe Kit and is indicated for:INTENDED USE The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) tissue specimens from non-small cell lung cancer (NSCLC) patients.INDICATION FOR USEThe Vysis ALK Break Apart FISH Probe Kit is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib) and ALUNBRIG (brigatinib) in accordance with the approved therapeutic product labeling."|FALSE|TRUE|33|1
147|P110012|S009|"VYSIS ALK BREAK APART FISH PROBE KIT|PROBECHEK ALK POSITIVE CONTROL SLIDES KIT|PROBECHEK ALK NEGATIVE CONTROL SLIDES KIT"|"fluorescence in situ hybridization| anaplastic lymphoma kinase| gene rearrangement"|2014-10-01 00:00:00|2015-07-02 00:00:00|APPROVAL FOR USE OF ABBOTT VP 2000 PROCESSOR AND A CORRESPONDING SET OFREAGENTS IN AN AUTOMATED SLIDE PROCESSING PROCEDURE.|FALSE|TRUE|33|1
148|P110012|S007|VYSIS ALK BREAK APART FISH PROBE KIT|"fluorescence in situ hybridization| anaplastic lymphoma kinase| gene rearrangement"|2014-08-14 00:00:00|2014-12-10 00:00:00|"APPROVAL FOR MODIFICATIONS TO THE PROBECHK ALK POSITIVE AND NEGATIVE CONTROL SLIDE LABELING| AND EXPANSION OF THE ASSAY GUARD BAND PARAMETERS."|FALSE|TRUE|33|1
149|P110020|S033|cobas 4800 BRAF V600 Mutation Test|somatic gene mutation detection system|2019-06-27 00:00:00|2019-09-25 00:00:00|Approval for a formulation change to the cobas DNA Sample Preparation Kit used with the cobas 4800 BRAF V600 Mutation Test (P110020). |FALSE|TRUE|34|1
150|P110020||COBAS 4800 BRAF V600 MUTATION TEST|somatic gene mutation detection system|2011-04-25 00:00:00|2011-08-17 00:00:00|"APPROVAL FOR THE COBAS 4800 BRAF V600 MUTATION TEST. THIS DEVICE IS INDICATED FOR: THE COBAS 4800 BRAF V600 MUTATION TEST IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION OF THE BRAF V600E MUTATION IN DNA EXTRACTED FROM FORMALIN-FIXED| PARAFFIN-EMBEDDED HUMAN MELANOMA TISSUE. THE COBAS 4800 BRAF V600 MUTATION TEST IS A REAL-TIME PCR TEST ON THE COBAS 4800 SYSTEM| AND IS INTENDED TO BE USED AS AN AID IN SELECTING MELANOMA PATIENTS WHOSE TUMORS CARRY THE BRAF V600E MUTATION FOR TREATMENT WITH VEMURAFENIB."|FALSE|TRUE|34|1
151|P110020|S010|COBAS BRAF V600 MUTATION TEST|somatic gene mutation detection system|2013-12-13 00:00:00|2014-03-12 00:00:00|APPROVAL FOR CHANGES TO THE COBAS 4800 SR2 SYSTEM SOFTWARE ARCHITECTURE AND ASSAY SPECIFIC ANALYSIS PACKAGE (ASAP) SOFTWARE FOR THE COBAS BRAF V600 MUTATION TEST AND COBAS EGFR MUTATION TEST.|FALSE|TRUE|34|1
152|P110020|S026|cobas BRAF V600 Mutation Test|somatic gene mutation detection system|2018-06-08 00:00:00|2018-07-05 00:00:00|Eliminate a duplicative in-process test for designated kit reagents.|FALSE|TRUE|34|1
153|P110020|S006|"ROCHE COBAS DNA SAMPLE PREPARATION KIT|059855536190 AND ROCHE COBAS 4800 BRAF V600 MUTATION KIT| 05985579190"|somatic gene mutation detection system|2012-09-12 00:00:00|2013-01-10 00:00:00|APPROVAL FOR THE ADDITION OF POLY RA TO THE BRAF MUTANT AND WILD-TYPE CONTROLS BUFFER MATRIX AND ASSOCIATED MANUFACTURING PROCESS CHANGES.|FALSE|TRUE|34|1
154|P110020|S016|"Roche cobas DNA Sample Preparation Kit| COBAS 4800 BRAF V600 MUTATION TEST"|somatic gene mutation detection system|2016-06-30 00:00:00|2016-11-07 00:00:00|"Approval for the cobas 4800 BRAF V600 Mutation Test. The cobas 4800 BRAF V600 Mutation Test is an in vitro diagnostic device intended for the qualitative detection of BRAF V600E mutation in DNA extracted from formalin-fixed| paraffin-embedded human melanoma tissue. The cobas 4800 BRAF V600 Mutation Test is a real-time PCR test on the cobas 4800 System| and is intended to be used as an aid in selecting melanoma patients for treatment with the targeted therapies listed in the table below| in accordance with the approved therapeutic product labeling: Therapeutic Therapeutic Indication Test ResultZELBORAF (vemurafenib) BRAF V600E Mutation DetectedCOTELLIC (cobimetinib)| in combination with ZELBORAF (vemurafenib) BRAF V600E or V600K* Mutation Detected* *Due to cross-reactivity by the cobas 4800 BRAF V600 Mutation Test| the clinical trial for cobimetinib| in combination with vemurafenib| included some patients whose tumor carried the BRAF V600K mutation. "|FALSE|TRUE|34|1
155|P160002||VENTANA PD-L1(SP142) CDX ASSAY|"immunohistochemistry assay| antibody| programmed death-ligand 1"|2016-01-13 00:00:00|2016-05-18 00:00:00|"Approval for the PD-L1(SP142) Assay. The device is indicated for the following: VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed| paraffin-embedded (FFPE) urothelial carcinoma tissue stained with OptiView DAB IHC Detection Kit and OptiView Amplifcation Kit on a VENTANA BenchMark ULTRA instrument. PD-L1 status is determined by the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity. PD-L1 expression in >= 5% IC determined by VENTANA PD-L1 (SP142) Assay in urothelial carcinoma tissue is associated with increased objective response rate (ORR) in a non-randomized study of TECENTRIQ (atezolizumab)."|FALSE|TRUE|35|1
156|P160002|S006|VENTANA PD-L1(SP142) CDX ASSAY|"immunohistochemistry assay| antibody| programmed death-ligand 1"|2018-06-14 00:00:00|2018-07-02 00:00:00|"Approval for modifying the intended use of the VENTANA PD-L1(SP142). The VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed| paraffin-embedded (FFPE) urothelial carcinoma and non-small cell lung cancer (NSCLC) tissue stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a VENTANA BenchMark ULTRA instrument. Determination of PD-L1 status is indication-specific| and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.PD-L1 expression in >= 5% IC determined by VENTANA PD-L1 (SP142) Assay in urothelial carcinoma tissue is indicated as an aid in identifying urothelial carcinoma patients for treatment with TECENTRIQ (atezolizumab).PD-L1 expression in >= 50% TC or >= 10% IC determined by VENTANA PD-L1 (SP142) Assay in NSCLC tissue may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).See the TECENTRIQ product label for PD-L1 expression cutoff values guiding therapy in specific clinical circumstances.This product is intended for in vitro diagnostic (IVD) use."|FALSE|TRUE|35|1
157|P160002|S009|VENTANA PD-L1(SP142) Assay.|"immunohistochemistry assay| antibody| programmed death-ligand 1"|2018-09-14 00:00:00|2019-03-08 00:00:00|"Approval for VENTANA PD L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD L1 clone SP142. The device is intended for use in the assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor-infiltrating immune cells in the formalin-fixed| paraffin-embedded (FFPE) tissues indicated below stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a VENTANA BenchMark ULTRA instrument. Determination of PD-L1 status is indication-specific| and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.VENTANA PD-L1 (SP142) Assay is indicated as an aid for identifying patients for treatment with the therapies for the respective cutoffs listed in Table 1 in accordance with the approved therapeutic product labeling. Table 1. Companion diagnostic indications for the VENTANA PD-L1 (SP142) Assay Indication for use Therapy Cutoff Urothelial Carcinoma TECENTRIQ >= 5% ICTriple-Negative Breast Carcinoma (TNBC) TECENTRIQ >= 1% ICPD-L1 expression in >= 50% TC or >= 10% IC determined by VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer (NSCLC) patients may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).This product should be interpreted by a qualified pathologist in conjunction with histological examination| relevant clinical information| and proper controls. This product is intended for in vitro diagnostic (IVD) use."|FALSE|TRUE|35|1
158|P180043|S001|therascreen FGFR RGQ RT-PCR Kit|somatic gene mutation detection system|2020-02-28 00:00:00|2020-08-18 00:00:00|"Approval for the therascreen FGFR RGQ RT-PCR Kit is a reverse transcription| real-time PCR test for the qualitative detection of two point mutations in exon 7 [p.R248C (c.742C>T)| p.S249C (c.746C>G)]| two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A>G)] and two fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3) in the fibroblast growth factor receptor 3 (FGFR3) gene in RNA samples derived from formalin-fixed paraffin-embedded (FFPE) urothelial tumor tissue. The test is indicated for use as an aid in identifying urothelial cancer (UC) patients who harbor these alterations and are therefore eligible for treatment with BALVERSA (erdafitinib). Specimens are processed using the RNeasy DSP FFPE Kit for manual sample preparation followed by reverse transcription and then automated amplification and detection on the Rotor-Gene Q MDx (US) instrument."|FALSE|TRUE|36|1
159|P180043||therascreen FGFR RGQ RT-PCR Kit|somatic gene mutation detection system|2018-11-08 00:00:00|2019-04-12 00:00:00|"Approval for the THERASCREEN FGFR RGQ PCR KIT. The Therascreen FGFR RGQ RT-PCR Kit is a real-time| reverse transcription PCR test for the qualitative detection of two point mutations in exon 7 [p.R248C (c.742C>T)| p.S249C (c.746C>G)]| two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A>G)] and two fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3) in the fibroblast growth factor receptor 3 (FGFR3) gene in RNA samples derived from formalin-fixed paraffin-embedded (FFPE) urothelial tumor tissue. The test is indicated for use as an aid in identifying urothelial cancer (UC) patients who harbor these alterations and are therefore eligible for treatment with BALVERSA (erdafitinib). Specimens are processed using the RNeasy DSP FFPE Kit for manual sample preparation followed by reverse transcription and then automated amplification and detection on the Rotor-Gene Q MDx (US) instrument."|FALSE|TRUE|36|1
160|P190004||therascreen PIK3CA RGQ PCR Kit|somatic gene mutation detection system|2019-02-15 00:00:00|2019-05-24 00:00:00|"Approval for the therascreen PIK3CA RGQ PCR Kit. The therascreen PIK3CA RGQ PCR Kit is a real-time qualitative PCR test for the detection of 11 mutations in the phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) gene (Exon 7: C420R; Exon 9: E542K| E545A| E545D [1635G>T only]| E545G| E545K| Q546E| Q546R; and Exon 20: H1047L| H1047R| H1047Y) using genomic DNA (gDNA) extracted from formalin-fixed| paraffin-embedded (FFPE) breast tumor tissue or circulating tumor DNA (ctDNA) from plasma derived from K2EDTA anticoagulated peripheral whole blood taken from patients with breast cancer. The test is intended to aid clinicians in identifying breast cancer patients who may be eligible for treatment with PIQRAY (alpelisib) based on a PIK3CA Mutation Detected result. Patients whose FFPE tissue or plasma specimen produce a positive therascreen PIK3CA RGQ PCR Kit test result for the presence of one or more PIK3CA mutations are eligible for treatment with PIQRAY (alpelisib). Patients whose plasma specimens produces a negative result using this test should be reflexed to testing with FFPE tumor tissue for the presence of PIK3CA mutations.FFPE tumor specimens are processed using the QIAamp DSP DNA FFPE Tissue Kit for manual sample preparation. K2EDTA anticoagulated whole peripheral venous blood plasma specimens are processed using the QIAamp DSP Circulating Nucleic Acid Kit for manual sample preparation. For both specimen types| the Rotor-Gene Q (RGQ) MDx (US) instrument is used for automated amplification and detection. The Kit is to be used by trained personnel in a professional laboratory environment."|FALSE|TRUE|37|1
161|P190014||myChoice HRD CDx|cancer-related germline gene mutation detection system|2019-05-03 00:00:00|2019-10-23 00:00:00|"Approval of Myriad myChoice CDx. Myriad myChoice CDx is a next generation sequencing-based in vitro diagnostic test that assesses the qualitative detection and classification of single nucleotide variants| insertions and deletions| and large rearrangement variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of Genomic Instability Score (GIS) which is an algorithmic measurement of Loss of Heterozygosity (LOH)| Telomeric Allelic Imbalance (TAI)| and Large-scale State Transitions (LST) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The results of the test are used as an aid in identifying ovarian cancer patients with positive homologous recombination deficiency (HRD) status for treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling.Table1---Tumor Type: Ovarian Cancer| Biomarker: Myriad HRD (defined as deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes and/or positive Genomic Instability Score)| Therapy: Zejula (niraparib)"|FALSE|TRUE|38|1
162|P190014|S002|myChoice CDx|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-02-05 00:00:00|2020-03-23 00:00:00|"Approval of the final revised labeling (IU) for the Myriad myChoice CDx. The device is a next generation sequencing-based in vitro diagnostic test that assesses the qualitative detection and classification of single nucleotide variants| insertions and deletions| and large rearrangement variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of Genomic Instability Score (GIS) which is an algorithmic measurement of Loss of Heterozygosity (LOH)| Telomeric Allelic Imbalance (TAI)| and Large-scale State Transitions (LST) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The results of the test are used as an aid in identifying ovarian cancer patients with positive homologous recombination deficiency (HRD) status who are eligible| because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes| or may become eligible| because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes or a positive Genomic Instability Score| for treatment with the approved targeted therapy for Zejula (niraparib)."|FALSE|TRUE|38|1
163|P190014|S001|myChoice CDx|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-01-23 00:00:00|2020-04-29 00:00:00|"Approval for extending the label claim to include an additional indication for Zejula (niraparib) maintenance therapy. The device| as modified| will be marketed under the trade name Myriad myChoice CDx and is indicated for:Myriad myChoice CDx is a next generation sequencing-based in vitro diagnostic test that assesses the qualitative detection and classification of single nucleotide variants| insertions and deletions| and large rearrangement variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of Genomic Instability Score (GIS) which is an algorithmic measurement of Loss of Heterozygosity (LOH)| Telomeric Allelic Imbalance (TAI)| and Large-scale State Transitions (LST) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The results of the test are used as an aid in identifying ovarian cancer patients with positive homologous recombination deficiency (HRD) status| who are eligible| because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes| or may become eligible| because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes or a positive Genomic Instability Score| for treatment with the approved targeted therapy Zejula (niraparib).Detection of deleterious or suspected deleterious BRCA1 and BRCA2 and/or positive Genomic Instability Score in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula (niraparib) maintenance therapy. This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories| Inc.| a single laboratory site located at 320 Wakara Way| Salt Lake City| UT 84108."|FALSE|TRUE|38|1
164|P190026||therascreen BRAF V600E RGQ PCR Kit|somatic gene mutation detection system|2019-09-30 00:00:00|2020-04-15 00:00:00|Approval for the therascreen BRAF V600E RGQ PCR Kit. The therascreen BRAF V600E RGQ PCR Kit is a real-time PCR test for the qualitative detection of V600E mutations in the BRAF gene using genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) human colorectal cancer (CRC) tumor tissue. The therascreen BRAF V600E RGQ PCR Kit is an in vitro diagnostic device intended to be used as an aid in selecting patients with metastatic colorectal cancer (mCRC) whose tumors carry the BRAF V600E mutation for treatment with BRAFTOVI (encorafenib) in combination with cetuximab. The therascreen BRAF V600E RGQ PCR Kit is for use on the Rotor-Gene Q MDx (US) instrument. The therascreen BRAF V600E RGQ PCR Kit is intended for in vitro diagnostic use. |FALSE|TRUE|39|1
165|P200014|S003|cobas EZH2 Mutation Test|somatic gene mutation detection system|2021-02-22 00:00:00|2021-08-10 00:00:00|Approval for the revised Instructions for Use for the cobas EZH2 Mutation Test.|FALSE|TRUE|41|1
166|P200014||cobas EZH2 Mutation Test|somatic gene mutation detection system|2020-03-02 00:00:00|2020-06-18 00:00:00|"Approval for The cobas EZH2 Mutation Test. The device is a real-time allele-specific PCR test for qualitative detection of single nucleotide mutations for Y646N| Y646F or Y646X (Y646H| Y646S| or Y646C)| A682G| and A692V of the EZH2 gene in DNA extracted from formalin fixed paraffin embedded (FFPE) human follicular lymphoma tumor tissue specimens. The cobas EZH2 Mutation Test is intended for the identification of follicular lymphoma patients with an EZH2 mutation for treatment with TAZVERIK (tazemetostat)| in accordance with the approved therapeutic product labeling."|FALSE|TRUE|41|1
167|P200010||Guardant360 CDx|Next generation sequencing oncology panel, somatic or germline variant detection system|2020-02-10 00:00:00|2020-08-07 00:00:00|"Approval order for Guardant360 CDx. Guardant360 CDx is a qualitative next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of single nucleotide variants (SNVs)| insertions and deletions (indels) in 55 genes| copy number amplifications (CNAs) in two (2) genes| and fusions in four (4) genes. Guardant360 CDx utilizes circulating cell-free DNA (cfDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). The test is intended to be used as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients who may benefit from treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling. Table 1. Companion Diagnostic IndicationsIndication: Non-small cell lung cancer (NSCLC); Biomarker: EGFR exon 19 deletions| L858R| and T790M*; Therapy: TAGRISSO (osimertinib)A negative result from a plasma specimen does not assure that the patient’s tumor is negative for genomic findings. NSCLC patients who are negative for the biomarkers listed in Table 1 should be reflexed to tissue biopsy testing for Table 1 biomarkers using an FDA-approved tumor tissue test| if feasible.*The efficacy of TAGRISSO (osimertinib) has not been established in the EGFR T790M plasma-positive| tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore| testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Additionally| the test is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with solid malignant neoplasms. The test is for use with patients previously diagnosed with cancer and in conjunction with other laboratory and clinical findings. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product. Guardant360 CDx is a single-site assay performed at Guardant Health| Inc."|FALSE|TRUE|43|1
168|P200010|S001|Guardant360 CDx|Next generation sequencing oncology panel, somatic or germline variant detection system|2020-11-20 00:00:00|2021-05-21 00:00:00|Approval order for extending the label claim to include an indication for RYBREVANT (amivantamab) in non-small cell lung cancer patients with EGFR exon 20 insertions.|FALSE|TRUE|43|1
169|P200010|S002|Guardant360 CDx|Next generation sequencing oncology panel, somatic or germline variant detection system|2020-12-18 00:00:00|2021-05-28 00:00:00|Approval of Guardant360 CDx for expanding the indications for use to include the companion diagnostic claim to identify non-small cell lung cancer patients with KRAS G12C mutation for treatment with LUMAKRASTM (sotorasib). |FALSE|TRUE|43|1
170|P200010|S005|Guardant360 CDx|Next generation sequencing oncology panel, somatic or germline variant detection system|2021-12-17 00:00:00|2022-03-16 00:00:00|Approval to use reagent lots interchangeably for Guardant360 CDx Sample Preparation Kit Boxes and a minor software update to accommodate the reagent interchangeability update.|FALSE|TRUE|43|1
171|P190032|S001|FoundationOne Liquid CDx (F1 Liquid CDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-08-28 00:00:00|2021-07-15 00:00:00|Approval to include a companion diagnostic indication for detection of MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping in non-small cell lung cancer patients who may benefit from treatment with TABRECTA (capmatinib)|FALSE|TRUE|44|1
172|P190032||FoundationOne Liquid CDx (F1 Liquid CDx)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2019-12-26 00:00:00|2020-08-26 00:00:00|"Approval for the FoundationOne Liquid CDx. The device is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology to detect and report substitutions| insertions and deletions (indels) in 311 genes| including rearrangements and copy number losses only in BRCA1 and BRCA2. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of cancer patients collected in FoundationOne Liquid CDx cfDNA blood collection tubes included in the FoundationOne Liquid CDx Blood Sample Collection Kit. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally| FoundationOne Liquid CDx is intended to provide tumor mutation profiling for substitutions and indels to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Table 1: Companion diagnostic indicationsTumor Type Biomarker(s) Detected TherapyNon-small cell lung cancer (NSCLC) EGFR exon 19 deletions andEGFR exon 21 L858R alteration IRESSA (gefitinib)TAGRISSO (osimertinib)TARCEVA (erlotinib)Prostate cancer BRCA1| BRCA2 alterations RUBRACA (rucaparib)A negative result from a plasma specimen does not mean that the patient’s tumor is negative for genomic findings. Patients who are negative for the mutations listed in Table 1 should be reflexed to routine biopsy and their tumor mutation status confirmed using an FDA-approved tumor tissue test| if feasible.Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product. FoundationOne Liquid CDx is a single-site assay performed at Foundation Medicine| Inc. in Cambridge| MA."|FALSE|TRUE|44|1
173|P200011||ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA)|"next generation sequencing oncology panel| somatic or germline variant detection system"|2020-02-18 00:00:00|2021-07-30 00:00:00|"Approval of the ONCO/RevealTM Dx Lung and Colon Cancer Assay (O/RDx-LCCA). The device is a qualitative next generation sequencing based in vitro diagnostic test that uses amplicon-based target enrichment technology for detection of single nucleotide variants (SNVs) and deletions in 2 genes from DNA isolated from formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients with NSCLC or CRC who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. The O/RDx-LCCA is intended to be used on the Illumina MiSeqDx instrument.Table 1. List of somatic variants for therapeutic useIndication Gene Variant Targeted therapyColorectal Cancer (CRC) KRAS KRAS wild-type (absence of mutations in codons 12 and 13) ERBITUX (cetuximab)| orVECTIBIX (panitumumab)Non-Small Cell Lung Cancer(NSCLC) EGFR Exon 19 Deletions and Exon 21 L858R Substitution Mutations EGFR Tyrosine Kinase Inhibitors approved by FDA**For the most current information about the therapeutic products in this group| go to: https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm301431.htm "|FALSE|TRUE|46|1
174|P160046||VENTANA PD-L1 (SP263) ASSAY|"immunohistochemistry assay| antibody| programmed death-ligand 1"|2016-10-20 00:00:00|2017-05-01 00:00:00|"Approval for the VENTANA PD-L1 (SP263) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the PD-L1 protein in formalin-fixed| paraffin-embedded (FFPE) urothelial carcinoma tissue stained with OptiView DAB IHC Detection Kit on a VENTANA BenchMark ULTRA instrument.PD-L1 status is determined by the percentage of tumor cells with any membrane staining above background or by the percentage of tumor-associated immune cells with staining (IC+) at any intensity above background. The percent of tumor area occupied by any tumor-associated immune cells (Immune Cells Present| ICP) is used to determine IC+| which is the percent area of ICP exhibiting PD-L1 positive immune cell staining. PD-L1 status is considered High if any of the following are met:1) >= 25% of tumor cells exhibit membrane staining; or|2) ICP > 1% and IC+ ? 25%; or|3) ICP = 1% and IC+ = 100%.PD-L1 High status as determined by VENTANA PD-L1 (SP263) Assay was associated with increased objective response rate (ORR) in a single arm study of IMFINZI (durvalumab)."|FALSE|TRUE|47|1
